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Respiratory Tract Infections
Bronchiolitis and pneumonia in early 
childhood have been associated with 
respiratory morbidity in adulthood, 
but the prospective research 
evidence in this area is limited. This 
longitudinal 30-year follow-up study 
investigated the adulthood outcome 
of bronchiolitis and pneumonia 
patients who were hospitalized 
at less than 2 years of age. The 
increased asthma risk was present 
at the age of 28-31 years after early 
childhood bronchiolitis, and lung 
function impairment and decreased 
quality of life after bronchiolitis and 
pneumonia. 
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ABSTRACT: 
 
Lower respiratory tract infections (LRTI´s) in childhood have been associated with 
respiratory morbidity and lung function disorders in adulthood, but so far the prospective 
data about the adulthood outcome of children with early childhood LRTI´s is scarce. 
In 1981-1982, 83 bronchiolitis and 44 pneumonia patients who were 
hospitalized at less than 2 years of age were enrolled in the study. Viral etiology of LRTI 
was determined from nasopharyngeal secretion (NPS) samples during hospitalization. 
Blood eosinophils were measured at hospital admission and on convalescence. In 2010, 48 
former bronchiolitis patients, 22 former pneumonia patients, and 138 population controls 
participated in the clinical study between the ages of 28-31 years. Saint George’s 
Respiratory Questionnaire (SGRQ) was used as a health-related quality of life (HRQoL) 
assessment tool. Participants underwent two-week peak expiratory flow (PEF) monitoring, 
spirometry with bronchodilatation test (BD), and skin prick testing. Asthma was defined as 
doctor-diagnosed or self-reported to determine the certainty of the diagnosis.  
 Asthma prevalence between the ages of 28-31 years was 31-35% in the 
bronchiolitis group, 9-23% in the pneumonia group, and 11-14% in the control group, with 
a significant difference between the bronchiolitis and control groups. Asthma prevalence 
after respiratory syncytial virus (RSV) LRTI was increased, if wheezing was present during 
LRTI. Forced vital capacity (FVC%), forced expiratory volume in one second (FEV1%), and 
FEV1/FVC-ratio% were all reduced in  bronchiolitis and FEV1% in pneumonia patients, all 
before and after BD. These findings demonstrated irreversible airway obstruction in 
adulthood. Eosinophilia outside the infection in early childhood predicted asthma in 
adulthood, whereas low eosinophil count during bronchiolitis protected from asthma. 
Parental history of asthma and eosinophilia during bronchiolitis were significant predictors 
for impaired lung function in adulthood. SGRQ scores were higher in former bronchiolitis 
and pneumonia patients compared to controls, indicating lower HRQoL in adulthood.  
 The current study demonstrates that increased risk for asthma continues up to 
the age of 28-31 years after early childhood bronchiolitis and after wheezing RSV LRTI. 
Irreversible airway obstruction is present in adulthood after bronchiolitis. Repeated 
wheezing and eosinophilia outside the infection predict asthma, whereas eosinopenia 
during infection protects from asthma in adulthood. Family history of asthma and 
eosinophilia during bronchiolitis predict lung function impairment in adulthood. 
Decreased HRQoL is present between the ages of 28-31 years after bronchiolitis and 
pneumonia.  
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TIIVISTELMÄ: 
 
Lapsuusiän alahengitystieinfektiot (AHI) on yhdistetty hengityselinsairauksiin ja 
keuhkojen toimintahäiriöihin aikuisiällä, mutta toistaiseksi prospektiivinen tutkimusnäyttö 
varhaislapsuudessa alahengitystieinfektioon sairastuneiden ennusteesta aikuisuudessa on 
vähäistä. 
 Tutkimukseen otettiin mukaan 83 bronkioliittiin ja 44 keuhkokuumeeseen alle 
2-vuotiaana sairastunutta lasta, jotka otettiin sairaalahoitoon vuosina 1981–82. AHI:n 
aiheuttajaviruksia tutkittiin nenänielun imulimanäytteestä sairaalaan otettaessa. Veren 
eosinofiilit määritettiin AHI:n aikana ja sen jälkeen. Vuonna 2010 48 entistä 
bronkioliittipotilasta, 22 keuhkokuumepotilasta ja 138 väestöverrokkia kutsuttiin kliiniseen 
seurantatutkimukseen 28–31 vuoden iässä. Saint Georgen sairaalan Keuhkosairauksia 
Koskevaa Kyselylomaketta käytettiin elämänlaatumittarina. Tutkimuksen yhteydessä 
toteutettiin tutkittaville 2 viikon PEF-seuranta, spirometiatutkimus 
bronkodilataatiokokeella sekä ihopistokokeet. Astma määritettiin lääkärin diagnosoimaksi 
tai itse raportoiduksi riippuen määritelmän tiukkuudesta. 
 Astman vallitsevuus 28–31 vuoden iässä oli bronkioliittiryhmässä 31–35%, 
keuhkokuumeryhmässä 9–23% ja verrokeilla 11–15%, ollen bronkioliittiryhmässä 
merkittävästi verrokkeja korkeampi. RSV:n aiheuttaman AHI:n jälkeen astman prevalenssi 
oli verrokkeja korkeampi, jos infektion aikana oli todettu hengityksen vinkunaa. 
Uloshengityksen nopea vitaalikapasiteetti (FVC%), uloshengityksen sekuntikapasiteetti 
(FEV1%) ja FEV1/FVC%-suhde olivat kaikki matalammat bronkioliitin jälkeen ja FEV1% 
keuhkokuumeen jälkeen sekä ennen että jälkeen bronkodilataatiokokeen, paljastaen 
palautumattoman hengitysteiden ahtautumisen aikuisiällä. Eosinofilia infektion jälkeen 
ennusti astmaa 28–31 vuoden iässä, kun taas matala eosinofiilitaso infektion aikana näytti 
suojaavan astmalta. Vanhempien astma ja eosinofilia AHI:n aikana ennustivat keuhkojen 
toimintamuutoksia aikuisuudessa. Korkeat SGRQ pisteet osoittivat bronkioliitti- ja 
keuhkokuumeryhmissä matalampaa elämänlaatua aikuisuudessa verrattuna 
kontrolliryhmään.  
 Tutkimuksemme osoittaa, että astmariski on kohonnut 28–31-vuotiaana 
varhaislapsuuden bronkioliitin jälkeen sekä vinkuvan RSV AHI:n jälkeen. Bronkioliitin 
jälkeen palautumattomaan hengitysteiden ahtautumiseen sopivat muutokset voidaan 
todeta aikuisiässä. Eosinofilia infektion jälkeen ennustaa astmaa, kun taas matalat 
eosinofiilit infektion aikana olivat suojaava tekijä. Vanhempien astma ja eosinofilia 
bronkioliitin aikana ennustivat keuhkojen toimintahäiriötä aikuisuudessa. Bronkioliitti ja 
keuhkokuumepotilailla on verrokkeja matalampi elämänlaatu 28–31-vuotiaana. 
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 1 Introduction 
Bronchiolitis is an acute, viral, lower respiratory tract infection that presents in early childhood 
(Nagakumar & Doull 2012, Oymar et al. 2014, Zorc & Hall 2010, Tapiainen et al. 2015). It is a 
common disease with symptoms varying from mild rhinorrhea and wheezing, treated at home, 
to severe breathing difficulties that require hospital care (Oymar et al. 2014, Ralston et al. 2014, 
Mecklin et al. 2014).  Bronchiolitis is usually considered as the first wheezing episode in young 
children (Jartti et al. 2009). However wheezing bronchitis is a common symptom also in older 
children and these conditions have a significant overlap (Brand et al. 2008).  
Lower respiratory tract infections (LRTI) like bronchiolitis and pneumonia in early 
childhood have been previously associated with increased respiratory morbidity like asthma 
(Piippo-Savolainen & Korppi 2008, Stern et al. 2008, Chan et al. 2015) and chronic obstructive 
pulmonary disease (COPD) (de Marco et al. 2011) in adulthood. 
 Wheezing is commonly associated with early childhood viral LRTI. About 30% of 
all children experience wheezing during the first years of their lives (Martinez et al. 1995, Brand 
et al. 2014, Henderson et al. 2008). It is also a heterogenous condition, and a majority of children 
grow out of the wheezing tendency as they get older (Martinez et al. 1995, Henderson et al. 
2008). However, in others, wheezing at an early age may be the first sign of persistent 
respiratory morbidity. These children continue to wheeze persistently and eventually may 
develop asthma later in life (Martinez et al. 1995, Henderson et al. 2008, Piippo-Savolainen et al. 
2004, Goksor et al. 2006, Sigurs et al. 2010). During the first years of life, the prevalence of 
wheezing is very high after hospitalization for severe bronchiolitis (Korppi et al. 1993, Kuikka et 
al. 1994). However, the tendency for wheezing and the asthma prevalence decline at school age 
down to 15-40%, before increasing again in early adulthood (Piippo-Savolainen et al. 2004, 
Goksor et al. 2006, Sigurs et al. 2010, Sigurs et al. 2000, Sigurs et al. 2005, Korppi et al. 1994, 
Kotaniemi-Syrjanen et al. 2002, Hyvarinen et al. 2005). 
 Respiratory syncytial virus (RSV) is the most common causative virus associated 
with lower respiratory tract infections like bronchiolitis and pneumonia in young children 
(Jartti et al. 2004, Miller et al. 2013, Stockman et al. 2012, Garcia et al. 2010). However, the more 
recently discovered human rhinovirus (HRV) comprises a considerable proportion of 
bronchiolitis cases (Miller et al. 2013, Midulla et al. 2010, Miron et al. 2010, Mansbach et al. 2012) 
and has also been associated with pneumonia in childhood (Cilla et al. 2008). Viral etiology of 
initial LRTI in early childhood seems to be a determinant for the subsequent outcome in later 
childhood and even in adulthood. RSV etiology of bronchiolitis has been associated with 
increased risk for asthma in childhood, with decreasing tendency in relation to increasing age 
(Regnier & Huels 2013). However, HRV etiology of initial bronchiolitis is associated with an 
even greater risk for asthma compared to RSV, probably due to associations with atopy and 
heredity for asthma (Kotaniemi-Syrjanen et al. 2003, Carroll et al. 2012, Jartti & Korppi 2011, 
Turunen et al. 2014).  
Because of the heterogenity of early childhood wheezing disorders, it has been a 
challenge to distinguish those children who are about to develop chronic respiratory disease 
and to target possible preventive actions. Huge efforts have been made to identify risk factors 
that could predict the risk for the development of chronic respiratory morbidity in wheezing 
children (Piippo-Savolainen et al. 2006, Castro-Rodriguez et al. 2000, Kurukulaaratchy et al. 
2003, Hafkamp-de Groen et al. 2013).  
Immunoglobulin E (IgE) -mediated atopy (Martinez et al. 1995, Piippo-Savolainen 
et al. 2006, Kusel et al. 2007, Kusel et al. 2012, Jackson et al. 2012) and blood eosinophilia 
(Kotaniemi-Syrjanen et al. 2002, Midulla et al. 2014, Ehlenfield et al. 2000) have been 
demonstrated to be important risk factors for the subsequent development of asthma in 
children with early childhood wheezing. Eosinopenia, whether during infection or persistently, 
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seems to protect from the development of asthma (Karakoc et al. 2002, Martinez et al. 1998). 
Other factors associated with the development of asthma after early childhood wheezing have 
included the following: family history of asthma (Goksor et al. 2006, Sigurs et al. 2010, Piippo-
Savolainen et al. 2006), maternal smoking during pregnancy (Goksor et al. 2007) or passive 
smoking in infancy (Goksor et al. 2007), and the recurrence of wheezing symptoms in early 
childhood (Piippo-Savolainen et al. 2006). 
In line with increased clinical respiratory morbidity, impaired lung function has 
also been described to be present in childhood after early childhood bronchiolitis (Sigurs et al. 
2005, Kotaniemi-Syrjanen et al. 2008, Hyvarinen et al. 2007) and pneumonia (Castro-Rodriguez 
et al. 1999). In previous studies, lung function tests have consistently demonstrated signs of 
irreversible obstruction at early adult age after early childhood bronchiolitis (Piippo-Savolainen 
et al. 2004, Sigurs et al. 2010, Sigurs et al. 2005, Goksor et al. 2008). However, there is an ongoing 
debate whether this lung function reduction is caused by viral LRTI or is merely a sign of 
premorbid lung function impairment, which has been described to associate with increased 
susceptibility to early LRTI´s (Martinez et al. 1988, Martinez et al. 1991, Tager et al. 1993, Young 
et al. 2000, Dezateux et al. 1999, Murray et al. 2002).  
In addition to lung function impairment, decreased quality of life has also been 
described 9 months and 3 years after bronchiolitis (Rolfsjord et al. 2015, Bont et al. 2004) and 
after pneumonia in the short-term (Shoham et al. 2005). However, studies in this field are 
scarce, and there are no previous studies on HRQoL after early childhood LRTIs including 
follow-ups to adolescence or adulthood. 
In conclusion, children with early childhood LRTIs form a heterogenous group 
with different outcomes in later life. Despite the active research activity in the field during the 
last decades, more efforts are needed to clarify the risk factors and the long-term outcome of 
these children, preferably in a prospective long-term setting. 
 We have followed up with a group of study subjects who were hospitalized for 
bronchiolitis or pneumonia before the age of 2 years in 1981-1982 (Piippo-Savolainen et al. 2004, 
Korppi et al. 1993, Kuikka et al. 1994, Korppi et al. 1994, Korppi et al. 1986). This study is the 
longest on-going prospective study about the long-term effects of early childhood LRTIs. Our 
aim was to evaluate the outcome of children with the history of early childhood LRTI in terms 
of asthma prevalence, health-related quality of life, and lung function in adulthood, with the 
special focus on RSV etiology of the initial LRTI in infancy.   
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2  Review of the Literature 
2.1 BRONCHIOLITIS AND PNEUMONIA IN EARLY CHILDHOOD 
2.1.1 Bronchiolitis and wheezing in early childhood 
Bronchiolitis is an acute, viral, lower respiratory tract infection that presents in early childhood 
(Nagakumar & Doull 2012, Oymar et al. 2014, Zorc & Hall 2010, Tapiainen et al. 2015). It is a 
self-limited disease, characterized by acute inflammation of small airways that leads to edema, 
mucus production, and necrosis of airway epithelium (Nagakumar & Doull 2012, Ralston et al. 
2014). There is no uniform definition of diagnostic criteria for bronchiolitis, but the most 
common clinical features and findings include rhinitis, breathing difficulties, cough, poor 
feeding, irritability, wheezing and/or crepitations on auscultation, and even apnoea in young 
babies (Oymar et al. 2014, Ralston et al. 2014, Mecklin et al. 2014). The severity of the disease 
varies from mild respiratory symptoms that are treated at home to severe respiratory distress 
that requires hospital care and even respiratory support. 
Bronchiolitis is a disease with a high disease burden, since about 30-40% of children 
develop bronchiolitis before the age of 2 years (Zorc & Hall 2010, Ralston et al. 2014). One out of 
ten bronchiolitis patients are admitted to the hospital because of the disease (Nagakumar & 
Doull 2012, Smyth & Openshaw 2006). However the need for hospitalization is more common 
in young age groups (Murray et al. 2014, Deshpande & Northern 2003), since over 90% of the 
hospitalized cases are under 12 months, and over 60% are under 6 months old (Deshpande & 
Northern 2003, Scottish Intercollegiate Guideline Network 2012). 
Bronchiolitis is usually defined as the first wheezing episode in childhood (Jartti et 
al. 2009). Several studies, and also current care guidelines, have used the age limit of 24 months 
for the diagnosis (Ralston et al. 2014, Scottish Intercollegiate Guideline Network 2012). 
However, recent European studies have applied the age limit of 12 months (Zorc & Hall 2010, 
Mecklin et al. 2014, Smyth & Openshaw 2006, Henderson et al. 2005), and this age limit is also in 
clinical use in Finland. 
There is a significant heterogenity in the definition of acute bronchiolitis in terms of 
age but also in terms of symptoms. This is crucial when we try to understand the differences in 
outcome studies of early childhood bronchiolitis. Mostly in the United Kingdom and Australia, 
the definition of acute bronchiolitis includes evidence of coryza, cough, airway obstruction, and 
crepitations on auscultation with or without wheezing (Elphick et al. 2007, Everard 2006). In 
North America and many other countries, the term “acute bronchiolitis” includes the evidence 
of audible wheezing (Elphick et al. 2007, Everard 2006).  
Evidently, RSV is the predominant virus associated with LRTIs, especially 
bronchiolitis and pneumonia, in children under 1 year of age (Jartti et al. 2004, Miller et al. 2013, 
Stockman et al. 2012, Garcia et al. 2010). Depending on the ages of enrolled patients, study 
design, and definition of bronchiolitis, RSV has comprised 40-80% of bronchiolitis cases needing 
hospitalization (Jartti et al. 2004, Miller et al. 2013, Midulla et al. 2010, Miron et al. 2010, 
Mansbach et al. 2012, Calvo et al. 2010). The primary infection occurs in young children, and re-
infections are common at any age (Miller et al. 2013, Calvo et al. 2010, Bezerra et al. 2011). RSV 
etiology of bronchiolitis has also been associated with more severe disease compared to other 
viruses (Miller et al. 2013, Garcia et al. 2010, Calvo et al. 2010, Bezerra et al. 2011, Hervas et al. 
2012). In temperate climates, RSV occurs as annual outbreaks usually between late autumn and 
early spring (Jartti et al. 2004, Hervas et al. 2012, Hall et al. 2013). 
Human rhinoviruses are the most common respiratory pathogens that cause upper 
respiratory infections in all age groups (Jartti et al. 2012). However, increasing evidence 
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suggests that rhonoviruses also comprise 10-30 % of bronchiolitis cases needing hospitalization 
(Miller et al. 2013, Midulla et al. 2010, Miron et al. 2010, Mansbach et al. 2012). In previous 
studies, children diagnosed with HRV bronchiolitis have been older and more likely atopic 
compared to children diagnosed with RSV bronchiolitis (Miller et al. 2013, Korppi et al. 2004). 
Human metapneumovirus has been found in 2-8% of bronchiolitis patients and 
human bocavirus in 5-8% (Jartti et al. 2004, Miller et al. 2013, Midulla et al. 2010, Miron et al. 
2010, Calvo et al. 2010, Bezerra et al. 2011, Soderlund-Venermo et al. 2009, Jartti et al. 2002, 
Schuster & Williams 2013). Metapneumovirus and bocavirus occur in older children compared 
to RSV (Calvo et al. 2010, Schuster & Williams 2013). In a Spanish study, half of the patients 
under 2 years old with bocavirus bronchiolitis were under 12 months old, and half of the 
metapneumovirus bronchiolitis patients were under 6 months old, while half of the children 
with RSV bronchiolitis were under 3 months old (Calvo et al. 2010). Co-infections of viruses in 
different combinations are also common (Calvo et al. 2010, Bezerra et al. 2011). Other viruses 
detected in bronchiolitis patients have been adenovirus, coronaviruses, influenza A and B 
viruses, and parainfluenzaviruses, especially type 3.  
2.1.2 Community acquired pneumonia in early childhood 
Pneumonia is an infection of lung tissue that can be caused by numerous viruses and bacteria 
(Stein & Marostica 2007). Community acquired pneumonia (CAP) can be defined as the 
presence of signs and symtoms of pneumonia in a previously healthy child due to an infection 
that has been acquired outside the hospital (Harris et al. 2011). 
The most common clinical symptoms and findings of pneumonia are tachypnoea, 
fever, and cough (Stein & Marostica 2007, Don et al. 2010). Clinical signs and symptoms of viral 
and bacterial pneumonia are highly variable and overlap (Ruuskanen et al. 2011, Cevey-
Macherel et al. 2009). Fever higher than 38·5°C, tachypnea, and chest recessions are suggestive 
of bacterial pneumonia. In comparison, young age, wheezing, fever less than 38·5°C, and 
striking chest recessions are suggestive of a viral cause (Harris et al. 2011, Ruuskanen et al. 
2011).  
Pneumonia can be diagnosed on a clinical basis (Harris et al. 2011). In addition to 
indicative symptoms of pneumonia, fine end-inspiratory cracles on auscultation can be present. 
Currently, the gold standard of pneumonia diagnosis is the presence of lung infiltration on a 
chest radiograph, even though in clinical practice the diagnosis can be made without imaging 
(Don et al. 2010). Interstitial infiltrates apparent on a chest radiograph are generally believed to 
suggest a viral cause of pneumonia, and alveolar infiltrates indicate a bacterial cause; but, these 
findings overlap (Ruuskanen et al. 2011). 
 The most common pathogen in CAP is Streptococcus pneumoniae (Juven et al. 2000), 
even though the introduction of pneumococcal vaccines has dramatically decreased 
pneumococcal pneumonia in those countries where the vaccine has been universally introduced 
(Weil-Olivier et al. 2012). Chlamydophila pneumoniae and Mycoplasma pneumoniae are common 
pathogens in older children (Juven et al. 2000, Don et al. 2005). Viral pneumonia is the most 
common in children under 2 years of age, whereas at school age bacterial etiology predominates 
(Ruuskanen et al. 2011, Juven et al. 2000, Pavia 2013). Mixed viral-viral and viral-bacterial 
infections are common (Cevey-Macherel et al. 2009, Juven et al. 2000, Don et al. 2005).  
In a Spanish study, the total prevalence of viral infection was 67% in chidren under 
3 years of age with CAP. RSV was found in 20%, rhinovirus in 14%, bocavirus in 14%, 
metapneumovirus in 12%, and parainfluenza viruses in 11% of children with CAP. Other agents 
detected were influenza, corona, and adenoviruses (Cilla et al. 2008). 
RSV is the most common virus that causes CAP in children (Cilla et al. 2008, Juven 
et al. 2000, Pavia 2013, Heiskanen-Kosma et al. 1998, Korppi 2002), and it is also the most 
common virus found in viral-bacterial mixed infections in children (Heiskanen-Kosma et al. 
1998). RSV accounts for almost 10% of all pneumonias in children at less than 2 years of age 
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(Deshpande & Northern 2003). The proportion of RSV etiology increses during RSV epidemic, 
accounting for 25-30% of pneumonias in children at less than 1 year of age (Deshpande & 
Northern 2003). The differential diagnosis of RSV bronchiolitis and pneumonia is challenging 
due to similar clinical symptoms being presented. So, it has also been suggested that RSV 
pneumonia is part of the same clinical entity than bronchiolitis (Piippo-Savolainen 2006).  
2.2 WHEEZING, ASTHMA AND COPD 
2.2.1 Wheezing phenotypes in preschool children 
Wheezing can be described as a high-pitched sound with a musical quality emitting from the 
chest during expiration (Elphick et al. 2001). A wheezing breathing sound is a result of the 
narrowing of the intrathoracic airways and expiratory flow limitation that can be a result of 
exposure to multiple triggers such as tobacco smoke, allergens or exercise (Brand et al. 2008). 
Definitions of wheezing used in children aged less than 6 years are very 
heterogenous (Brand et al. 2008). The term bronchiolitis is usually used for the first wheezing 
episode in the youngest age group (Jartti et al. 2009, Brand et al. 2008), although the age limit of 
the definition varies (Zorc & Hall 2010, Ralston et al. 2014, Scottish Intercollegiate Guideline 
Network 2012). However, wheezing is also a common symptom in older children (Brand et al. 
2008, Saglani 2013). Terms like “wheezing bronchitis”, “wheezy bronchitis, “virus-associated 
wheezing”, “viral-induced wheezing” and “asthmatic bronchitis” have been used to describe 
wheezing in children (Tapiainen et al. 2015, Saglani 2013, Wennergren 2003). Thus, wheezing in 
children under three years of age covers two clinical conditions: wheezing bronchitis and 
bronchiolitis (Tapiainen et al. 2015). However, in previous literature, both of these conditions 
are often include in the same trials (Tapiainen et al. 2015). Thus, bronchiolitis and wheezing 
bronchitis have a significant overlap (Brand et al. 2008). 
Wheezing during childhood is a common condition since approximately 30% of all 
children experience wheezing before the age of three years (Martinez et al. 1995, Brand et al. 
2014, Henderson et al. 2008). A majority wheezing children become asymptomatic by the age of 
8 years (Martinez et al. 1995, Henderson et al. 2008), while others continue to wheeze and are 
prone to develop chronic asthma. So, early childhood wheezers form a heterogenous group of 
children with different types of risk factors, triggers, and severity of wheezing as well as 
different kinds of sequelae from childhood to old age. Several attempts have been made to 
classify these wheezing children in order to identify the different phenotypes of wheezing that 
might predict outcomes in childhood and even in adulthood. 
 In the 1990´s, the Tucson Children´s Respiratory Study introduced a classification 
for wheezing children that was based on the onset and duration of wheezing symptoms 
(Martinez et al. 1995). The majority of children (60%) who experienced wheezing during the 
first three years of life did not exhibit wheezing at the age of six. These children were classified 
as early transient wheezers. These transient wheezers form a group of children who have 
wheezing symtoms at a very early age during viral infections but no longer later in life 
(Martinez et al. 1995, Taussig et al. 2003). In the Tucson study, these children were more likely 
to have mothers who smoked and lower levels of lung function (i.e., maximal expiratory flow at 
functional residual capacity, VMax FRC) as infants compared to those children who never 
wheezed. However, these children did not present factors associated with allergic diathesis, 
such as family history of asthma, high IgE levels, atopic dermatitis, or rhinitis apart from colds 
(Martinez et al. 1995, Taussig et al. 2003). 
 Children who experienced wheezing at the age of 6 years were classified as non-
atopic or atopic wheezers. Those children, who were classified as non-atopic wheezers, still 
experienced wheezing at the age of 6 years, but they did not have any atopic disease. Atopic 
wheezers were divided into two groups: early atopic wheezers who had early symptoms that 
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continued at the age of 6 years and late atopic wheezers who did not have symtoms at early age 
but experienced wheezing at the age of six years. Both groups were equally sensitized to 
aeroallergens at the age of 6 years. However, early atopic wheezers had the lowest lung 
function levels of all groups at the ages of 6 and 11 years and highest IgE levels at the same age, 
respectively (Taussig et al. 2003). 
 The Tucson classification of wheezing phenotypes has been criticized to be of less 
importance in a clinical practice due to its retrospective view. In 2008, the European Respiratory 
Society (ERS) introduced a new classification of wheezing phenotypes that were based on the 
temporal pattern of wheezing: Episodic (viral) wheeze (EVW) and multiple trigger wheeze 
(MTW) (Brand et al. 2008). EVW is defined as discrete wheezing episodes that occur usually 
during viral respiratory infections. MTW wheeze, however, is defined as wheezing that shows 
discrete exacerbations but also with symptoms between these episodes (Brand et al. 2008). 
 This guideline was widely accepted into clinical use, but it was also criticized 
because it does not take the severity or frequency of wheezing episodes into account. In 2014, a 
consensus group published a new report that summarized new evidence and proposed some 
modifications. The report agreed that the severity and frequency of wheezing symptoms are 
stronger predictors of long term outcome than distinction of EVW and MTW (Brand et al. 2014). 
 Asthma often has its origins in childhood (Stern et al. 2008, Wenzel 2012), with half 
of the adults who have asthma experiencing their first symptoms during childhood (Simpson & 
Sheikh 2010). In children, however, the diagnosis of asthma can be difficult due to a high 
prevalence of wheezing in young age groups. Previous classification of different wheezing 
phenotypes has attempted to recognize those wheezing children who will develop asthma in 
the future. However, because of significant overlap of phenotypes and shifting from one class to 
another, the development of chronic asthma is still hard to predict in clinical practice. 
  
2.2.2 Characteristics of Asthma 
According to the Global Initiative for Asthma (GINA) 2014 report, asthma is a heterogenous 
disease, usually characterized by chronic airway inflammation (Global Initiative for Asthma 
2014). It is diagnosed based on the history of respiratory symptoms, such as wheeze, shortness 
of breath, chest tightness, and cough that vary over time and in intensity. In addition to asthma 
presumptive symtoms the diagnosis of asthma in over 6-years-old children and adults requires 
evidence of variable expiratory airflow limitation.  Airway hyperreactivity to different stimuli, 
e.g., allergens, exercise, or viral respiratory infections is often associated with asthma (Global 
Initiative for Asthma 2014). 
Asthma is one of the most common chronic diseases in the world and is recognized 
as a major public health problem throughout the world (Masoli et al. 2004). In the cross-
sectional World Health Survey, implemented by the WHO, the global prevalence of asthma was 
approximately 4% (To et al. 2012). However, the prevalence of asthma varied as much as 21-fold 
amongst the 70 countries studied (To et al. 2012). In Finnish studies, the prevalence of asthma 
has been 7% among school schildren (Hugg et al. 2008), 3% in 16 year old adolescents, and 5% 
in 32 year old adults (Huurre et al. 2004). In studies also including older adults, the prevalence 
of physician-diagnosed asthma in Finland has been 8-9% (Pallasaho et al. 2011, Laatikainen et 
al. 2011). 
 Asthma is diagnosed based on respiratory symptoms suggestive for asthma as well 
as based on documented findings of variable airflow limitation (Global Initiative for Asthma 
2014). Characteristic changes in flow-volume spirometry (FVS) are considered as the most 
reliable indicators of variable airflow limitation. Increase in FEV1 by 200ml and 12% in adults, 
or 12% in children from the baseline after bronchodilator administration is considered the 
diagnostic for asthma (Global Initiative for Asthma 2014). In addition, the average daily diurnal 
variability of 10% in adults and 13% in children in peak expiratory flow (PEF) values during the 
two-week PEF follow-up are considered diagnostics for astma (Global Initiative for Asthma 
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2014). In Finnish current care guidelines PEF daily diurnal variability of 20% or increase by 15% 
from the baseline after bronchodilator administration are considered diagnostic for asthma 
(Asthma: Current Care Guidelines 2012). A variable airflow limitation may also be present in 
exercise test or in bronchial challenge test. Other possible diagnostic finding in FVS is a 
significant increase in FEV1 after treatment with anti-inflammatory medication (Global 
Initiative for Asthma 2014).  
 Asthma is a phenotypically heterogeneous disorder that results from a combination 
of various genetic and environmental factors (Wenzel 2012, Bel 2004). Due to this heterogeneity, 
patients with asthma can be divided into different phenotypes,(Wenzel 2012, Bel 2004, de Nijs et 
al. 2013). 
The best-described asthma phenotype is allergic asthma, which often begins during 
childhood (Global Initiative for Asthma 2014, Bel 2004, de Nijs et al. 2013). Although the 
majority of children with wheezing during their preschool years have a favorable outcome, 
some of these children show ongoing airway inflammation and eventually develop asthma that 
may persist up to adulthood (Stern et al. 2008, Bel 2004, de Nijs et al. 2013). Early-onset allergic 
asthma is characterized by T-helper 2 (TH2) -type immunological responses, increased 
immunoglobulin E (IgE) production and allergic diseases like atopic eczema or allergic rhinitis 
(Wenzel 2012, Bel 2004, de Nijs et al. 2013). However, low levels of IgE and a lack of 
responsiveness to corticosteroids in some children with asthma suggest that not all early-onset 
asthma is associated with allergies (Wenzel 2012). Some children with early-onset asthma have 
a remission during puberty, but develop symptoms again in early adulthood (Stern et al. 2008, 
Bel 2004).  
There is also a population of patients who develop their first asthma symptoms in 
adulthood (Wenzel 2012, de Nijs et al. 2013). In contrast to early-onset asthma, adult-onset 
asthma is less commonly associated with allergies (Wenzel 2012, Tuomisto et al. 2015). The 
prognosis of adult-onset asthma is not as favorable as cases of early-onset asthma (Tuomisto et 
al. 2015). Phenotypes such as late-onset eosinophilic, exercise-induced, obesity-related and 
neutrophilic have been suggested (Wenzel 2012, Tuomisto et al. 2015). Increasing evidence 
suggests that even though asthma is a single clinical diagnosis, the term “asthma” instead 
describes a group of clinical symptoms with variable expiratory airflow limitation (Wenzel 
2012). 
 
2.2.3 COPD 
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and 
mortality in the world, although the defined prevalence varies depending on the population 
studied, differences in study methods and the prevalence of risk factors such as tobacco smoke 
(Global Initiative for Chronic Obstructive Lung Disease 2014, Celli et al. 2004, Zeng et al. 2012). 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as a common 
preventable and treatable disease. It is characterized by persistent airflow limitation and is 
usually progressive (Global Initiative for Chronic Obstructive Lung Disease 2014, Celli et al. 
2004). COPD is further characterized by chronic inflammatory responses in the airways and the 
lung that are caused by inhaled noxious particles or gases, usually tobacco smoke (Global 
Initiative for Chronic Obstructive Lung Disease 2014, Celli et al. 2004). 
 Diagnosis of COPD is based on typical clinical symptoms, which are dyspnea, 
chronic cough and sputum production in patients who have a history of exposure to COPD risk 
factors (Global Initiative for Chronic Obstructive Lung Disease 2014, Chronic obstructive 
pulmonary disease: National Clinical Guideline Centre 2014). In addition to these symptoms, 
COPD diagnosis requires the presence of persistent airflow limitation, confirmed by spirometry 
(Global Initiative for Chronic Obstructive Lung Disease 2014, Chronic obstructive pulmonary 
disease: National Clinical Guideline Centre 2014). According to GOLD standards, spirometric 
criterion for persistent airflow limitation, and therefore COPD, is a fixed ratio of post-
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bronchodilator FEV1/FVC below 0.70 (Global Initiative for Chronic Obstructive Lung Disease 
2014). However, using this fixed cut-off limit can lead to an underdiagnosis of young adults and 
an overdiagnosis of older people (Swanney et al. 2008, Pellegrino et al. 2005). Therfore, 
American Thoracic Society (ATS) and ERS have proposed that classification should be based on 
a FEV1/FVC ratio below the lower limit of normality (LLN), i.e., more than 1.64 standard 
deviations (SD) below the predicted level (5th percentile), for the specific age group, sex and 
height (Pellegrino et al. 2005). 
 Tobacco smoking has long been recognized as the single most important risk factor 
for COPD (Global Initiative for Chronic Obstructive Lung Disease 2014, Zeng et al. 2012, 
Landau 2008). However, recent data have demonstrated that non-smokers comprise a 
substantial proportion of individuals with COPD (Zeng et al. 2012, Lamprecht et al. 2011). In 
addition to tobacco smoke, genetic susceptibility and exposure to other inhaled particles have 
been shown to increase the risk for COPD (Global Initiative for Chronic Obstructive Lung 
Disease 2014, Zeng et al. 2012).  
Asthma has also been recognized as a risk factor for development of COPD (Global 
Initiative for Chronic Obstructive Lung Disease 2014, Lamprecht et al. 2011). A classical sign of 
asthma is evidence of variable airflow limitation in the spirometry test (Global Initiative for 
Asthma 2014). However, after 40 years of age, persistent airflow limitation, which is 
characteristic of COPD, becomes more common in the population with respiratory symptoms 
(Global Initiative for Asthma 2014, Global Initiative for Chronic Obstructive Lung Disease 
2014). Asthma and COPD, therefore, have a significant overlap, and a high proportion of adult 
patients who have a chronic respiratory disease present symptoms and findings from both 
diseases (Global Initiative for Asthma 2014, Global Initiative for Chronic Obstructive Lung 
Disease 2014). 
 It has also been established that early childhood respiratory infections, like 
bronchiolitis and pneumonia, are associated with an increased risk for COPD later in life (de 
Marco et al. 2011, Barker et al. 1991). In addition, any other factor that hampers lung growth 
during gestation or childhood can lead to impaired lung function in adulthood and increase the 
risk for COPD in the future (de Marco et al. 2011, Global Initiative for Chronic Obstructive Lung 
Disease 2014, Barker et al. 1991). 
2.3 COHORT STUDIES EXPLORING ASTHMA DEVELOPMENT AFTER EARLY 
CHILDHOOD LRTI AND WHEEZING 
The link between early childhood respiratory infections and later respiratory morbidity has 
been an issue of interest during recent decades, and an association has been found between 
LRTIs in early childhood and later respiratory problems, such as asthma or COPD in adulthood 
(de Marco et al. 2011, Piippo-Savolainen et al. 2004, Svanes et al. 2010, Goksor et al. 2015). 
2.3.1 Birth cohort studies 
Over 130 birth cohort studies focusing on the development of asthma and allergies have been 
initiated over the past 30 years (Bousquet et al. 2014). Most of these have not continued follow-
ups beyond childhood ages. In this thesis, we present prospective birth cohort studies that have 
continued from childhood to adolescence or adulthood and have also focused on early lung 
function and early respiratory infections and their association with later outcome.  
 
The Tucson Children's Respiratory Study 
This prospective, long-term birth cohort study was started in the beginning of the 1980´s. The 
purpose of the study was to determine the risk factors for acute lower respiratory tract illnesses 
in early childhood and for chronic obstructive airway diseases in later life. A total of 1246 
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newborns were enrolled into the study, and 176 infants underwent lung function testing and 
maximal flow at functional residual capacity (V’maxFRC) soon after birth (Martinez et al. 1995, 
Martinez et al. 1988). Lung function testing was repeated at the ages of 6, 11, 16, and 22 years 
(Taussig et al. 2003, Stern et al. 2007, Morgan et al. 2005). During the first three years of life, a 
careful collection of data on respiratory symptoms and respiratory infections was collected.  
Serum IgE levels were measured at birth and at the ages of 9 months and 6 years. The latest 
follow-up of the subjects was published at the age of 22 years (Stern et al. 2008). The Tucson 
birth cohort is thus far the longest published prospective birth cohort study focused on the 
sequelae of early respiratory illnesses (Stern et al. 2008, Taussig et al. 2003, Stern et al. 2007). 
One of the main objectives of the study has been to explore how lung function in 
infancy is associated with morbidity and lung function later in life. The Tucson study 
demonstrated that low V’maxFRC in infancy is associated with an increased risk of LRTI in 
infancy (Martinez et al. 1991). In addition, infant lung function correlated with all 
measurements of airway function at ages 11–22 years. This demonstrates that lung function 
trajectories are determined early in life (Stern et al. 2007). 
In the Tucson birth cohort, 33% of all children experienced wheezing during LRTI 
before the age of three years, and almost 50% of all children had experienced wheezing at some 
stage of their lives before the age of 6 years (Martinez et al. 1995). For the first time, the Tucson 
birth cohort demonstrated the fact that had been suspected for a long time on a clinical basis: 
about 60% of children who experience wheezing along with respiratory infection before the age 
of 3 years grow out of this tendency by the age of 6 years (Martinez et al. 1995). Later it was 
demonstrated that the majority of these transient wheezers remain asymptomatic at the ages of 
11, 16, and 22 years of age (Stern et al. 2008, Taussig et al. 2003, Morgan et al. 2005). However, 
age at the time of the initial LRTI is an importat predictive factor, since the younger the child 
has wheezing, the more unlikely will be the tendency for wheezing to continue later. More than 
80% of children who wheeze during the first year of life do not wheeze later in life, whereas 
60% of those wheezing during the second year and 30% to 40% of those wheezing during the 
third year do not wheeze in later life (Taussig et al. 2003). Even though in the majority of 
children wheezing is a benign symptom, 40% of children with wheezing before the age of 3 
years continue to wheeze later in childhood as well (Martinez et al. 1995, Taussig et al. 2003). In 
the Tucson birth cohort, 46 % of children with persistent wheezing had been given a diagnosis 
of asthma by the age of six years (Martinez et al. 1995). So, in a proportion of children, early 
wheezing is a sign of developing asthma (Martinez et al. 1995). The Tucson birth cohort 
demonstrated that the wheezing patterns established at the age of 6 persist up to the age of 16 
and 22 years (Stern et al. 2008, Morgan et al. 2005). In over 70% of cases with current asthma at 
the age of 22 years, the first wheezing episode had happened before the age of 6 years (Stern et 
al. 2008). The results of the Tucson birth cohort study documented, at least to the age of 22, that 
adulthood asthma, including asthma with early adulthood onset, has its origin in early 
childhood (Stern et al. 2008). 
   
The Melbourne Asthma Study 
The Melbourne Asthma study followed 484 study subjects from a 1957 birth cohort up to the 
age of 50 years (Phelan et al. 2002, Tai et al. 2014). Children with a past history of wheezing 
were recruited at the age of 7 years and an early childhood history was collected 
retrospectively. The original study group was divided into 5 groups: no wheezing history 
control, mild wheezy bronchitis (less that 5 episodes), wheezy bronchitis (5 or more episodes), 
asthma (wheezing not related to respiratory tract infections) and severe asthma (persistent 
symptoms, FEV1/FVC-ratio 50% or less) (Phelan et al. 2002, Grad & Morgan 2012). The subjects 
were subsequently reviewed at ages of 10, 14, 21, 28, 35, 42 and 50 years (Phelan et al. 2002, Tai 
et al. 2014). During the course of the study, it became evident that children with wheezy 
bronchitis had a very favorable outcome, whereas only a small proportion of those with 
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persistent symptoms, i.e., asthma or severe asthma, achieved remission of symptoms. 
Approximately 60% of children with wheezy or mild wheezy bronchitis were symptom free at 
the age of 42 years, whereas only 30% of study subjects with asthma and 10% with severe 
asthma had a remission of symptoms (Horak et al. 2003).  There were not significant changes in 
the asthma remission rates at the age of 50 years compared to age 42 years;  64% of those with 
wheezy or mild wheezy bronchitis, 47% of those with persistent asthma and 15% of those with 
severe asthma in childhood were symptom free, while the rest were diagnosed as having 
asthma (Tai et al. 2014). A majority of the study subjects in the wheezy bronchitis group reached 
remission before the age of 10 years (Tai et al. 2014). Severe childhood asthma, female sex and 
childhood hay fever were predictors of asthma at the age of 50 years (Tai et al. 2014).  
 At the beginning of the study, subjects with wheezy bronchitis had a comparable 
FEV1 and FEV1/FVC-ratio to controls. However the FEV1 and FEV1/FVC-ratio were lower in 
children with asthma. Lung function was established by the age of 10, and the differences 
between groups did not increase significantly even though symptoms persisted up to the age of 
50 years (Tai et al. 2014). Despite the ongoing symptoms in asthma groups, no further decline in 
the FEV1/FVC ratio was seen at the age of 50 years (Tai et al. 2014).  
 
Perth infant asthma follow-up (PIAF)  
The Australian Perth birth cohort of 253 babies has been followed up from birth up to the age of 
18 years (Young et al. 1991, Turner et al. 2002, Mullane et al. 2013). Lung function test 
(V’maxFRC) and bronchial hyperreactivity were studied at the ages of 1, 6 and 12 months 
(Young et al. 1991, Turner et al. 2009). Study subjects were followed up annually by 
questionnaires up to the age of 6 years (Turner et al. 2002). At 11 years of age, children 
underwent an assessment that included spirometry, airway responsiveness to histamine, and 
skin prick testing (Turner et al. 2002). Lung function testing was repeated at the age of 18 years 
(Mullane et al. 2013). This study has mainly concentrated on evaluating the impact of early lung 
function on future morbidity. Half of the 160 children who completed the early childhood 
follow-up had wheezing during the first 2 years of their lives (Young et al. 2000). Maternal 
antenatal smoking was associated with wheezing during the first year of life and the persistence 
of wheezing up to the age of 2 years (Young et al. 2000). Maternal asthma was associated only 
with wheezing during the first year of life (Young et al. 2000). The Perth birth cohort 
demonstrated the association between increased bronchial hyperreactivity at the age of 12 
months and childhood asthma at the age of 11 years (Turner et al. 2009). Among the 116 
subjects assessed at both 12 months and 11 years, asthma was present in 27% of children with 
increased bronchial hyperreactivity at both ages and 0% in those who did not have increased 
bronchial hyperreactivity at either age (Turner et al. 2009). Bronchial hyperreactivity that 
persisted from infancy to childhood was associated with male gender, early respiratory illness, 
and maternal smoking and asthma (Turner et al. 2009). Low lung function soon after birth was 
associated with wheezing in infancy (Young et al. 2000), at the age of 4 years (Turner et al. 2002) 
and the age of 18 years (Mullane et al. 2013). 
 
Copenhagen Prospective Studies on Asthma in Childhood (COPSAC)  
COPSAC is a prospective birth cohort of 411 children who were enrolled during the first month 
of life (Bisgaard 2004). All children were born to mothers with asthma. Lung function testing 
was completed in 403 neonates and again by age 7 in 317 children (Bisgaard et al. 2012).  It was 
demonstrated that lung function abnormalities increase the risk of bronchiolitis in young 
children (Chawes et al. 2012) and asthma in older children (Bisgaard et al. 2012). The harmful 
effect of environmental tobacco smoke exposure to lung function development in childhood 
was again demonstrated (Bisgaard et al. 2012). The COPSAC group recenty demonstrated that 
asthma at the age of 7 was associated with the number of respiratory infections, but not the 
specific viral trigger (Bonnelykke et al. 2015). In addition duration of wheezy episodes in early 
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childhood was found to be independent of the microbial trigger (Carlsson et al. 2015). These 
findings have underlined the importance of host factors in the development of asthma in 
wheezing children instead of specific viral triggers (Bonnelykke et al. 2015, Carlsson et al. 2015). 
 
The Environment and Childhood Asthma birth cohort study (ECA) 
This Norwegian birth cohort study was established in 1992 in Norway. This study included 
3754 children, of whom 802 had lung function measured at birth and at 10 and 16 years. Data 
has been obtained so far at the 2, 10, and 16 year investigations (Lodrup Carlsen et al. 1997, 
Lodrup Carlsen et al. 1999, Lodrup Carlsen et al. 2006, Hovland et al. 2013, Lodrup Carlsen et 
al. 2014).  The risk factors for impaired lung function early in life were studied. It was found 
that maternal smoking during pregnancy was associated with low lung function in newborn 
babies (Lodrup Carlsen et al. 1997). In addition, it was demonstrated that low lung function, 
measured soon after birth, is a risk factor for LRTIs in infancy and obstructive airway disease 
later in childhood (Lodrup Carlsen et al. 1999). The natural course of early childhood wheezing 
until adolescence was studied, and children with recurrent bronchial obstruction before the age 
of 2 years were demonstrated to have reduced lung function and more frequent bronchial 
hyperreactivity at 16 years compared with those with no wheezing or asthma (Hovland et al. 
2013). In addition, only one third of the children with recurrent bronchial obstruction by 2 years 
of age were found to be free from asthma medication, asthma symptoms, or bronchial 
hyperreactivity by 16 years of age (Hovland et al. 2013). 
 
Children, Allergy, Milieu, Stockholm, Epidemiological Survey (Bamse)  
The Bamse cohort was collected between 1994 and 1996 in Stockholm, Sweden. Four thousand 
eighty nine children were enrolled soon after birth, and the cohort has been followed-up by 
repeated questionnaires from early childhood up to the age of 16 years. Questionnaires were 
administered at 1, 2, 4, 8, 12, and 16 years of age. At the ages of 4 and 8 years, children were also 
invited to a clinical examination (Hallberg et al. 2010, Ballardini et al. 2012, Ekstrom et al. 2015). 
FVS was conducted at the ages of 8 and 16 years. At the age of 8 years, 9% of the cohort were 
classified as having transient asthma (symtoms only before the age of 4 years), 3% had late-
onset asthma (symtoms only after 4 years of age) and 4% had persistent asthma (symtoms at 4 
years and 8 years of age) (Hallberg et al. 2010). Children with persistent asthma had 
significantly reduced lung function at the age of 8 years and had more atopic diseases like 
eczema or rhinitis. At the age of 16 years, all asthma groups had a lower FEV1 and FEV1/FVC-
ratio compared to controls with no wheezing history (Hallberg et al. 2015). The lowest lung 
function values were seen for the early persistent asthma group (Hallberg et al. 2015).  Early 
childhood factors such as maternal body mass index, maternal smoking, gender, and exposure 
to air pollution and their association with respiratory morbidity up to the age of 16 were 
studied (Ekstrom et al. 2015, Lannero et al. 2006, Melen et al. 2004, Gruzieva et al. 2013).  
2.3.2 Prospective studies on viral LRTI 
There are number of post-bronchiolitis cohort studies currently taking place in the world. 
However, only four prospective post-bronchiolitis studies, started in the 1980’s and 1990´s 
including two in Sweden and two in Finland, have continued beyond puberty (Sigurs et al. 
2010, Goksor et al. 2015, Ruotsalainen et al. 2013, Ruotsalainen et al. 2010a). Thus far, two of the 
cohorts have been followed up to between the ages of 15-18 years (Sigurs et al. 2010, 
Ruotsalainen et al. 2013), and two cohorts have been followed up to between the ages of 25-29 
years (Goksor et al. 2015, Ruotsalainen et al. 2013). In these studies, bronchiolitis in infancy has 
been unanimously associated with increased risk of asthma up to adult age (Sigurs et al. 2010, 
Goksor et al. 2015, Ruotsalainen et al. 2013, Ruotsalainen et al. 2010a). 
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1980’s Finnish bronchiolitis and pneumonia study 
The follow-up of the 1980's Finnish bronhiolitis and pneumonia study (Kuopio, Finland) has 
continued for 30 years and has included several clinical follow-ups. It is thus far the longest 
active post-bronchiolitis study in the world. 
During admission to hospital in 1981-1982, viral or Mycoplasma pneumoniae etiology 
was found in 71/127 bronchiolitis and pneumonia patients under 2 years of age. RSV was 
responsible for 51/127 admissions (Korppi et al. 1986). At the age of 1-2 years, subsequent 
wheezing was present in 76% of bronchiolitis patients and in 9% of pneumonia patients (Korppi 
et al. 1993). At the age if 2-3 years, the respective figures were 58% in bronchiolitis patients and 
16% in pneumonia patients (Korppi et al. 1993). Atopic eczema and elevated IgE-levels during 
admission to hospital were more common in children with bronchiolitis compared to 
pneumonia patients (Korppi et al. 1993). 
At the age of 4.5-6 years, the prevalence of asthma was 25% in former bronchiolitis 
patients, and the results confirmed that children with atopy were at a greater risk for 
developing asthma later in childhood than non-atopics (Kuikka et al. 1994). 
At the 8-10 year follow-up, asthma risk was increased after bronchiolitis in infancy; 
asthma was present in 15% of bronhiolitis patients, 7% of pneumonia patients, and 2% of 
controls (Korppi et al. 1994). Bronchial hyperreactivity in the methacoline inhalation challenge 
and bronchial obstruction in spirometry were significantly more common in bronchiolitis and 
pneumonia patients compared to controls.  
In the posted questionnaire between the ages of 13-16 years, the prevalence of 
asthma was 14% in the original bronchiolitis patents and 12% in the pneumonia patients. By the 
less strict asthma criteria, the prevalence of asthma was 23% and 15% in the two groups, 
respectively (Hyvarinen et al. 2005).  
In the 20-year follow-up of the cohort, current physician-diagnosed asthma was 
present in 30% of the bronchiolitis patients, in 15% of the pneumonia patients, and in 11% of the 
controls (Piippo-Savolainen et al. 2004). Bronchiolitis patients had asthma significantly more 
often than controls. By less strict asthma criteria, the corresponding figures were 41% in 
bronchiolitis patients, 24% in pneumonia patients, and 11% in controls. In lung function testing, 
lung function abnormalities were present in former bronchiolitis patients more often compared 
to controls (Piippo-Savolainen et al. 2004). 
In the latest follow-up conducted as a postal questionnaire study at the age of 26-29 
years, doctor-diagnosed asthma was present in 20% and self-reported asthma was present in 
41% of former bronchiolitis patients. Asthma prevalence was significantly higher by both 
definitions compared to controls (Ruotsalainen et al. 2010a).  
 
Swedish post-bronchiolitis study 
One hundred and one children, aged less than 2 years and hospitalized for bronchiolitis in 1984-
1985, were enrolled in the study ((Wennergren et al. 1992). At re-investigation, when the 
children were 3-6 years old, 53% were free from asthmatic symptoms, 33% had mild asthma, 
and 8% and 6% had moderate and severe asthma, respectively (Wennergren et al. 1992). At the 
age of 10 years, 20% had mild asthma, 8% and 2% had moderate and severe asthma, 
respectively, and the majority of the study subjects were symptom-free (Wennergren et al. 
1997). The histamine challenge test was initiated at the age of 10 years, and bronchial 
hyperreactivity correlated with the clinical disease. However, no association was seen between 
the RSV etiology of the disease and asthma. This cohort has been reinvestigated between the 
ages of 17-20 years (Goksor et al. 2006) and between the ages of 25-28 years (Goksor et al. 2015). 
Between the ages of 17-20, 43% of the subjects had asthma, and 27% were classified as having 
mild asthma and and 16% had moderate or severe asthma, respectively. The risk of having 
asthma was 4 times higher in the bronchiolitis cohort compared to controls. Between the ages of 
25-28 years, current doctor-diagnosed asthma was present in 37% of the study subjects, and 50% 
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of these had moderate or severe asthma compared to 7% asthma prevalence in controls (Goksor 
et al. 2015). 
 
Swedish post-RSV bronchiolitis study 
A Swedish RSV bronchiolitis cohort was collected in 1989-90 (Sigurs et al. 1995). Forty seven 
children hospitalized for bronchiolitis before the age of one year, and 93 controls attended the 
follow-up studies at the ages of 1 and 3 years. Allergen specific IgE for foods and inhalant 
allergens was measured at the second follow-up. Later, the study subjects were invited to 
follow-up at the ages of 7, 13, and 18 years (Sigurs et al. 2010, Sigurs et al. 2000, Sigurs et al. 
2005). FVS with the bronchodilatation test and the dry air challenge test were performed at the 
ages of 13 and 18 years.  
At the age of 3 years, 23% of study subjects in the RSV group had asthma compared 
to 1% in controls. (Sigurs et al. 1995) In addition, 40% had experienced wheezing during the 
preceding year compared to 9% in controls. RSV bronchiolitis was a risk factor for asthma even 
without a family history of asthma. However, the combination of asthma heredity and 
bronchiolitis further increased asthma risk significantly. Atopy was also significantly more 
common in RSV bronchiolitis patients compared to controls.  
At the age of 7, the prevalence of current asthma was 23% in RSV bronchiolitis 
patients and 2% in controls (Sigurs et al. 2000). Prevalence of current asthma/recurrent 
wheezing was also increased at the ages of 13 (43%) and 18 (39%) years compared to controls 
with respective figures of 8% and 9% (Sigurs et al. 2010, Sigurs et al. 2005). Allergy has been 
significantly more common after RSV bronchiolitis compared to controls in every follow-up of 
this cohort, but this finding has not been confirmed in other studies. FVS before and after 
bronchodilatation was conducted at the ages of 13 and 18 years, and the main finding was a 
mild bronchial obstruction before and after the bronchodilatation test (Sigurs et al. 2010, Sigurs 
et al. 2005). 
 
1990’s Finnish viral wheezing study 
For this study, 100 children hospitalized for bronchiolitis in 1992-93 were recruited at the age of 
less than 2 years (Reijonen & Korppi 1998). Seven viruses were studied by antigen detection 
from the nasopharyngeal aspirates (NPA), and later PCR was used for detection of 
rhinoviruses. Five clinical follow-up visits were organized during the first 3 years after the 
hospitalization, and later this cohort has been re-investigated at the mean ages of 7, 12, and 16.5 
years (Kotaniemi-Syrjanen et al. 2002, Ruotsalainen et al. 2013, Reijonen & Korppi 1998, 
Reijonen et al. 2000, Hyvarinen et al. 2005). At the ages of 1 and 3 years, 49% and 52%, 
respectively, of wheezing children had experienced more than 2 wheezing episodes and were 
diagnosed as having asthma (Reijonen & Korppi 1998). At 7 and 11 years of age, 40% of study 
the subjects had asthma (Kotaniemi-Syrjanen et al. 2002, Hyvarinen et al. 2005)).  
 At the latest follow-up between the ages of 15-18 years, 30% of the study subjects 
had doctor-diagnosed asthma and 64% had self-reported asthma, which was significantly more 
compared to 5% and 11% in population-based controls, respectively (Ruotsalainen et al. 2013). 
Self-reported asthma was more common in former rhinovirus bronchiolitis patients compared 
to RSV bronchiolitis patients.  
2.3.3 Pneumonia and asthma 
Studies investigating the association with early childhood pneumonia and asthma are scarce 
compared to studies about bronchiolitis, wheezing, or asthma. In the Tucson birth cohort, 
pneumonia before 3 years of age was associated with a 3-fold risk of asthma at the age of 6 and 
11 years compared to children with no respiratory infections in early childhood (Castro-
Rodriguez et al. 1999). In the recent follow-up of the same cohort, pneumonia was associated 
with increased asthma risk at the age of 26 (Chan et al. 2015). However, the results of the 
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previous follow-up of the current cohort at the age of 18-20 years are controversial since asthma 
prevalence after early childhood pneumonia was not increased compared to controls (Piippo-
Savolainen et al. 2004).  
 
Table 1. Prevalence of recurrent wheezing or asthma after hospitalization for bronchiolitis in four 
prospective post-bronhiolitis cohorts, followed-up to adulthood. 
 
 
Asthma prevalence after hospitalization for bronchiolitis 
Age 
Finnish post-
bronchiolitis study 
Swedish post-
bronchiolitis study 
Swedish post-RSV 
bronchiolitis study 
Finnish viral wheezing 
study 
1-2# 76%1   49%15 
2-3# 58%1  63%11 52%16 
3-6 25%2 47%7   
7-10 15%3 30%8 23%12 40%17 
11-16 14%4  43%13 40%18 
17-20 30%5 43%9 39%14 30% (15-18 yrs)19 
25-29 20%6 37%10   
#Recurrent wheezing 
References: 1Korppi 1993, 2Kuikka 1994, 3Korppi 1994, 4Hyvärinen 2005, 5Piippo-Savolainen 2004, 
6Ruotsalainen 2010, 7Wennergren 1992, 8Wennergren 1997, 9Goksör 2006, 10Goksör 2014, 11Sigurs 
1995, 12Sigurs 2000, 13Sigurs 2005, 14Sigurs 2010, 15Reijonen 1998, 16Reijonen 2000, 17Kotaniemi-
Syrjänen 2002, 18Hyvärinen 2005, 19Ruotsalainen 2013 
2.3.4 Summary 
Early childhood wheezing, usually associated with viral LRTI, is very common, and 
approximately 30% of children experience wheezing before the age of 3 years (Martinez et al. 
1995). Birth cohorts that continued through to adulthood have demonstrated that the outcome 
of early childhood wheezing and asthma is determined during the childhood years.  Children 
with persistent or severe wheezing continue to have persistent symptoms or relapse in 
adolescence or adulthood (Stern et al. 2008, Phelan et al. 2002, Tai et al. 2014, Hovland et al. 
2013). However, early childhood intermittent wheezing during respiratory infections has a 
more favorable outcome, since approximately 60% of these children achieve remission later in 
life (Stern et al. 2008, Martinez et al. 1995, Tai et al. 2014).  
 The prevalence of asthma after hospitalization for early childhood LRTI in different 
ages is summarized in Table 1. At the age of 2-3 years, the prevalence of repeated wheezing 
after hospitalization for bronchiolitis has been 52-63% in post-bronchiolitis studies (Korppi et al. 
1993, Sigurs et al. 1995, Reijonen et al. 2000) (Table 1). However, the asthma prevalence declines 
at school age, being 15-40% at the age of 7-10 years (Sigurs et al. 2000, Korppi et al. 1994, 
Kotaniemi-Syrjanen et al. 2002, Wennergren et al. 1997) (Table 1). In adolescence, the prevalence 
of asthma increases again, and between the ages of 17-20 years, the prevalence of athma rises to 
30-43% (Piippo-Savolainen et al. 2004, Goksor et al. 2006, Sigurs et al. 2010). Later in adulthood, 
the prevalence of asthma seems to obtain a steady state between 20-37% (Goksor et al. 2015, 
Ruotsalainen et al. 2010a). Increased risk for asthma after early childhood pneumonia has been 
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demonstrated up to the age of 11 years (Castro-Rodriguez et al. 1999), but in adulthood the 
outcome in regards to asthma is controversial (Chan et al. 2015, Piippo-Savolainen et al. 2004). 
2.4 FACTORS ASSOCIATED WITH THE DEVELOPMENT OF ASTHMA AFTER 
EARLY CHILDHOOD WHEEZING 
The development of asthma in wheezing children is complex and not fully understood. A 
number of factors contribute to an individual´s risk to develop asthma. These can be classified 
as host factors including genetic features, obesity and sex, and environmental factors including 
allergens, respiratory infections, microbial effects, medication, exposure to tobacco smoke, and 
air pollution (Global Initiative for Asthma 2014). The development of asthma probably requires 
multiple exposures that can in genetically predisposed individuals interact and result in the 
development of asthma (Turner & Devereux 2007). 
 
2.4.1 Virus or the host factors: Do viral LRTIs cause asthma? 
 
As mentioned earlier, RSV is undoubtedly the most important virus causing LRTI in young 
children (Jartti et al. 2004, Miller et al. 2013, Stockman et al. 2012, Garcia et al. 2010).  RSV LRTI 
has been found to be a risk factor for wheezing as well as asthma in childhood in several studies 
(Henderson et al. 2005, Sigurs 2002, Martinez 2003, Escobar et al. 2013, Fjaerli et al. 2005, 
Schauer et al. 2002, Singleton et al. 2003, James et al. 2013). In the Tucson birth cohort, children 
with RSV LRTI in infancy were 3 to 5 times more likely to wheeze at the age of 6 years 
compared to those with no LRTI (Taussig et al. 2003, Stein et al. 1999). However, this association 
decreased with age and turned insignificant by the age of 13 years (Taussig et al. 2003, Stein et 
al. 1999). In a recent systematic review and meta-analysis, it was demonstrated that RSV 
hospitalizations were associated with a significantly increased risk of wheezing and asthma in 
childhood (odds ratio: 3.84; 95%CI: 3.23–4.58) (Regnier & Huels 2013). However, as presented in 
the Tucson birth cohort, the association between RSV hospitalization and asthma decreased 
with age at the follow-up (Regnier & Huels 2013). In adulthood this association has been more 
controversial; some studies demonstrate increased risk for asthma in adulthood (Sigurs et al. 
2010), while others do not (Korppi et al. 2004).  
There is strong epidemiological evidence that RSV increases wheezing symptoms 
and prevalence of asthma during childhood. However, these studies have not described the 
mechanism for this association. It has been demonstrated that RSV causes cytopathic effects in 
the airway epithelium of the growing lung, leading to extensive damage of the airway 
epithelium (Rossi & Colin 2015, Piedimonte 2001, Jafri et al. 2004, You et al. 2006, Becnel et al. 
2005). In addition, experimental studies based on animal models have demonstrated that RSV is 
able to induce neurogenic inflammation that results in long-term airway hyperreactivity, a 
characteristic of asthma (Rossi & Colin 2015, Piedimonte 2001, Jafri et al. 2004). It has been 
suggested RSV could act as a direct inducer of childhood wheezing and asthma by these 
mechanisms (Rossi & Colin 2015). However, there are enoumous gaps in our knowledge about 
the causality of these associations. 
 Viruses other than RSV have been described to associate with an even greater risk 
of asthma compared to RSV-induced wheezing (Kotaniemi-Syrjanen et al. 2003, Ruotsalainen et 
al. 2013, Reijonen et al. 2000, Piippo-Savolainen et al. 2007, Mikalsen et al. 2012). In a 7-year 
follow-up of a Finnish viral wheezing cohort, it was for the first time demonstrated that 
rhinovirus etiology of bronchiolitis is associated with a 10-fold increase in the risk of asthma 
compared to those hospitalized for RSV bronchiolitis (Kotaniemi-Syrjanen et al. 2003). Later, 
several studies have confirmed this finding, and evidently rhinovirus-induced wheezing in 
early childhood is a risk factor for future asthma (Kotaniemi-Syrjanen et al. 2003, Jartti & Korppi 
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2011, Jartti & Korppi 2011, Jackson et al. 2008, Lehtinen et al. 2007); also, this association seems 
to continue at least up to the ages of 15-18 years (Ruotsalainen et al. 2013). More specifically, it 
was demonstrated in the 1990’s Finnish viral wheezing study that risk for asthma is increased 
between the ages of 15-18 years after the RSV and rhinovirus bronchiolitis when compared with 
population-based controls with no history of bronchiolitis (Table 2). However, when comparing 
the bronchiolitis groups, those with history of rhinovirus bronchiolitis had a higher risk for 
asthma compared to RSV bronchiolitis patients (Ruotsalainen et al. 2013). 
 HRVs induce limited cytotoxicity in airway epithelium (Rossi & Colin 2015). 
However, release of pro-inflammatory mediators during HRV infection can lead to recurrent or 
persistent bronchial hyperreactivity, especially in the presence of other predisposing factors 
(Rossi & Colin 2015, Schneider et al. 2012, Hong et al. 2014). In epidemiological studies, the 
susceptibility to rhinovirus-induced wheezing in infancy has been linked to a predisposition to 
other conditions, such as atopy, eosinophilic activity and maternal asthma (Kotaniemi-Syrjanen 
et al. 2003, Carroll et al. 2012, Jartti & Korppi 2011, Turunen et al. 2014). It has been concluded 
that there may be a subgroup of infants with early-life respiratory allergy who are prone to 
wheeze during rhinovirus infections.  
It has been suggested that host factors in children with early LRTI might explain 
the differences in the outcomes of long-term studies better than the type of virus (Elphick et al. 
2007, Everard 2006). More specifically, increased risk for respiratory symptoms and atopy has 
been reported in those children who present only wheezing symptoms during RSV LRTI 
(Elphick et al. 2007). Children who present bronchiolitis as characterised by widespread 
crepitations with or without wheeze do not differ from controls in regards to atopy and 
respiratory symptoms (Elphick et al. 2007). Due to these findings, it has been concluded that 
host factors rather than viral factors influence the phenotype of the initial illness and that the 
same host factors influence later outcomes (Elphick et al. 2007). A large Danish twin study 
studied the causation and the direction of causation between RSV hospitalization and asthma 
between 3-5 years of age (Thomsen et al. 2009). Asthma risk was significantly increased in the 
study subjects with a history of RSV bronchiolitis hospitalization. However the researchers 
were only able to demonstrate the causal relationship between asthma and RSV, whereas the 
causal link between RSV infection and asthma was rejected (Thomsen et al. 2009). However, in a 
prospective multicenter study, it was demonstrated that preventing RSV LRTI in premature 
infants with an anti-RSV monoclonal antibody, palivizumab, reduces subsequent recurrent 
wheezing in childhood. This suggests an independent role of RSV as an inducer of childhood 
wheezing (Simoes et al. 2007). This finding was especially seen in children who did not have an 
atopic predisposition and it was concluded that the predisposition to recurrent wheezing by is 
an atopy-independent mechanism (Simoes et al. 2010). 
It has been suggested that the association between early childhood viral LRTIs and 
subsequent asthma are more in favor of the hypothesis that the association between viral 
infection and asthma is due to shared predisposition rather than to a causal effect of virus 
(Thomsen et al. 2009, Kuehni et al. 2009). Thus, wheezing during LRTI, especially during 
rhinovirus infection, might merely reveal children who are already predisposed to asthma on 
the basis of host risk factors, such as abnormal lung function or immune response. However, 
there is growing evidence, based primarily on animal studies, that viruses are cabable of 
altering immune responses, especially in young children. This produces airway hyperreactivity 
and induces long-term wheezing and the development of asthma (Rossi & Colin 2015, 
Piedimonte 2001, Jafri et al. 2004, You et al. 2006, Becnel et al. 2005). Despite the increasing 
epidemiological and experimental data supporting an important role for viruses in the 
pathogenesis of wheezing and asthma, the underlying mechanism of this effect remains mainly 
unexplained (Rossi & Colin 2015). 
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2.4.2 Atopy and allergy  
Evidently, atopy increases the risk for persistent wheezing and asthma in later childhood in 
children who present early childhood wheezing illness (Martinez et al. 1995, Kusel et al. 2007, 
Kusel et al. 2012, Jackson et al. 2012). In children, the stepwise increase of symptoms called the 
“atopic march” starts with allergic sensitization and is often accompanied by eczema in the first 
year of life. These children are prone to develop allergic rhinitis and asthma in later life 
(Lambrecht & Hammad 2014). As seen in Table 1, atopy in early childhood is associated with 
current asthma up to between the ages of 18-20 years compared to non-atopic early wheezers 
(Piippo-Savolainen et al. 2006). However, early atopy seems to lose its significance as a 
predictor for asthma by the age of 27, as seen in Swedish and Finnish post-bronchiolitis cohorts 
(Goksor et al. 2015, Ruotsalainen et al. 2010a). Instead, current allergy was significantly 
associated with asthma in adulthood in these studies (Goksor et al. 2015, Ruotsalainen et al. 
2010a). 
 In a Swedish RSV bronchiolitis cohort, the risk for allergic rhinitis and allergic 
sensitization was significantly increased after the early RSV bronchiolitis up to the age of 18 
years compared to controls with no history of RSV LRTI (Sigurs et al. 2010, Sigurs et al. 2005). 
Thus, RSV might have provoked the development of atopy. However, as the study subjects 
were recruited at the time of the hospitalization, it was not possible to determine the underlying 
susceptibility for atopic diseases of the study subjects before RSV infection.  
The interaction between viral infections and atopy is clearly complex, and there is 
not a consensus about the causality between these conditions. Both viral infections and allergic 
inflammation can damage airway epithelium, and it has been proposed that the viral and 
atopy-associated inflammation may interact synergistically, eventually leading to persistent 
respiratory morbidity (Kusel et al. 2007, Siegle et al. 2010). To support the idea of synergistic 
interaction between atopy and LRTIs, it has been demonstrated that at the age of 5 years the 
highest risk for persistent wheezing after RSV or rhinovirus LRTI is present in those children 
who present atopy by the age of 2 years (Kusel et al. 2007, Kusel et al. 2012). 
 Taken together, the interaction between atopy, early childhood LRTIs, and 
subsequent persistent wheezing in later life is evident. While the causal relationship between 
these conditions remains unclear, there is growing evidence that pre-existing immunological 
status of the child matters when evaluating the outcome of early childhood LRTIs. 
  
2.4.3 Altered immunology 
It has been proposed that the delay in the maturation of the immune system plays an important 
role in the development of asthma (Lemanske 2002). After birth, a conversion from a 
predominant TH2 -type immunity shifts to a balance between T-helper 1 -type and TH2-type 
responses. In atopic children, this maturation is delayed, which allows TH2-type responses to 
persist. TH2-type responses stimulate the production of cytokines that regulate the allergen-
specific synthesis of IgE regulated by interleukin (IL)-4, the recruitment of eosinophils regulated 
by IL-5, the recruitment and growth of mast cells regulated by IL-9, and airway hyperreactivity 
that is characteristic for asthma (Kim et al. 2010). In contrast, TH1-type responses are 
characterized by an enhanced production of IL-2 and interferon gamma (IFN-γ). The delayed 
production of IFN-γ may predispose young children to environmental factors like aeroallergens 
or viruses that again may enhance adverse effects to the developing lungs (Lemanske 2002). 
To support the idea of allergic hypothesis it was demonstrated in the 6-years 
follow-up of the Tucson cohort that serum IgE levels were significantly higher at the age of 9 
months in those who were about to continue wheezing at the age of 6 years compared to non-
wheezers (Martinez et al. 1995). IgE-mediated specific allergic sensitization in childhood has 
also been recognized as a risk factor for asthma in childhood (Hyvarinen et al. 2005, Stoltz et al. 
2013, Simpson et al. 2010). However, this association between early sensitization and asthma 
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seems to lose its significance in adulthood (Ruotsalainen et al. 2010a, Piippo-Savolainen et al. 
2007b).  
 
2.4.4 Eosinophilic inflammation 
Eosinophils are granulocytes that develop in bone marrow, and are then released into the blood 
and subsequently migrate to peripheral tissues, usually to the thymus or gastrointestinal tract 
(Rosenberg et al. 2013). The activation of TH2-lymphocytes and chemokines in the eotaxin 
family leads to inflammation that stimulates the activation of eosinophils, which then migrate 
to the sites of inflammation (Lambrecht & Hammad 2014, Rosenberg et al. 2013). It has been 
established that eosinophil dysregulation contributes to the development of allergic diseases 
and asthma (Rosenberg et al. 2013, Phipps et al. 2007). However, eosinophils also have 
beneficial roles in host defense. In recent years, it has been it has been demonstrated in animal 
models that eosinophils promote viral clearance during viral respiratory infections and may 
thus limit virus-induced lung dysfunction (Phipps et al. 2007, Percopo et al. 2014). These 
interactions between eosinophils and viruses have not yet been fully studied. 
Recruitment of eosinophils to lung tissue is part of the pathophysiology of asthma. 
Most current evidence suggests that subepithelial fibrosis in the airways, which is a 
characteristic of allergic asthma, is mediated by eosinophilic inflammation (Lambrecht & 
Hammad 2014, Rosenberg et al. 2013, Zagai et al. 2004). Eosinophils contain several cytotoxic 
substances, such as eosinophil cationic protein (ECP), that can promote inflammation and cause 
tissue damage to the lungs (Zagai et al. 2004). High blood eosinophils during early viral 
infection have been recognized as a risk factor for asthma in childhood (Kotaniemi-Syrjanen et 
al. 2002, Midulla et al. 2014, Ehlenfield et al. 2000). This association has been demonstrated up 
to the ages of 15-18 years (Ruotsalainen et al. 2013) but not thereafter (Ruotsalainen et al. 2010a) 
(Table 2). Decrease in eosinophils seems to be the normal response to viral infection in infants 
during lower respiratory infection (Ehlenfield et al. 2000, Rosenberg et al. 2009). In line with 
this, children who are to become persistent wheezers have no eosinopenic reaction during LRTI 
(Karakoc et al. 2002, Martinez et al. 1998). In addition, persistently low blood eosinophil count 
in the population-based study has been recognized to associate with decreased risk for asthma 
up to the age of 13 years (Karakoc et al. 2002). Later it was demonstrated in the 20-year follow-
up of the present cohort that blood eosinophils were significantly lower on admission for 
bronchiolitis than on convalescence if the study subjects did not have doctor-diagnosed asthma 
or lung function deficiency between the age of 18-20 years (Piippo-Savolainen et al. 2007a). This 
association, suggesting an eosinopenic response to infection, was more evident in former RSV 
positive than RSV negative bronchiolitis patients (Piippo-Savolainen et al. 2007a). Also, a French 
study presented that the absence of eosinophilia alone predicted 91% of remissions of wheezing 
in infants (Just et al. 2008). 
The allergic pathway including TH2-derived IgE production, IgE-mediated allergic 
sensitization, and eosinophilia is clearly important in the development of asthma. However, the 
causal relationship and underlying host-factors related to these findings in early childhood 
wheezers remain to be solved. 
 
2.4.5 Heredity 
It has been known for a long time that the development of asthma after early childhood 
wheezing has a genetic component. This association has been demonstrated in epidemiological 
studies as increased risk of asthma in those with a family history and in particular with a 
maternal history of asthma (Martinez et al. 1995). In a 7-year follow-up of a Swedish RSV-
bronchiolitis cohort, it was demonstrated that those children with both a family history of 
asthma and bronchiolitis had higher rates of asthma (38%) compared to those with a family 
history of asthma or bronchiolitis alone (Sigurs et al. 2000). Family history of asthma increases 
the risk for asthma up to early adulthood (Stern et al. 2008, Goksor et al. 2006, Sigurs et al. 2010, 
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Piippo-Savolainen et al. 2006, Goksor et al. 2015) (Table 1). However, in a Swedish RSV 
bronhiolitis cohort, family history of asthma lost its significance as a risk factor for asthma in 
early adulthood (Sigurs et al. 2010). Parental atopy has not been a risk factor for future asthma 
in any of the long-term post-bronchiolitis studies (Sigurs et al. 2010, Piippo-Savolainen et al. 
2006, Goksor et al. 2015). However, in birth cohorts, family history of atopy has been described 
to be one of the most important risk factors for childhood persistent asthma (Nordlund et al. 
2014). 
 Asthma has a significant genetic contribution; heritability estimates vary between 
35% and 95% (Ober & Yao 2011). Many studies have demonstrated associations with single 
nucleotide polymorphisms (SNPs) at chromosome 17q21 and childhood onset asthma (Ober & 
Yao 2011). It has been described that 17q21 variants enhance the association between early 
respiratory infections and early-onset asthma. Risk genotypes also increase the association 
between infection and childhood asthma that remits in adulthood (Smit et al. 2010). 17q21 
variants also have a role in the development of HRV wheezing illnesses during early childhood. 
The increased risk for asthma among children with at-risk genotypes has been present in those 
children who had HRV wheezing illnesses in early life but not in those with RSV wheezing 
illnesses (Caliskan et al. 2013). So, there may be other underlying risk factors that increase the 
risk for both rhinovirus infection and asthma. It is also possible that rhinovirus infection acts as 
one in genetically susceptible children. 
 
2.4.6 Gender 
Wheezing in early life is more common in boys than in girls (Taussig et al. 2003, Melen et al. 
2004). In addition, the incidence of asthma is higher in boys up to adolescence (Taussig et al. 
2003). However, during adolescence the reversal of sex distribution is seen, and by the age of 
22-23 years asthma becomes more common in females (Stern et al. 2008, Anderson et al. 1992). 
The female gender also predicts the persistence of wheezing symptoms from childhood to 
adulthood (Sears et al. 2003). 
 
 
2.4.7 Parental smoking 
The relationship between maternal smoking during pregnancy or passive smoking in infancy 
and later asthma in children has been established in numerous studies (Martinez et al. 1995, 
Sigurs et al. 2010, Goksor et al. 2007, Tager et al. 1993, Lannero et al. 2006, Nordlund et al. 2014, 
Burke et al. 2012). In a recent review and meta-analysis, it was concluded that pre- or postnatal 
passive smoke exposure was associated with a 30% to 70% increase in the risk of wheezing and 
a 21% to 85% increase in asthma before the age of 2 years (Burke et al. 2012). In the same review, 
the strongest significant association was found between prenatal maternal smoking and 
incidence of asthma in children aged less than 2 years. The effect of prenatal maternal smoking 
became progressively weaker in relation to asthma incidence with increasing age. However, it 
remained significantly associated with asthma onset between the ages of 5 and 18 years (Burke 
et al. 2012). 
In a Swedish post-bronchiolitis cohort, it was demonstrated that both pre- and post-
natal smoke exposure are risk factors for asthma in adulthood and also in a high risk post-
bronchiolitis population (Table 2) (Goksor et al. 2007). However, in this same cohort, maternal 
smoking during pregnancy and passive smoking in infancy lost their association with asthma 
between the ages of 25-28 years (Goksor et al. 2015). 
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Table 2. Early factors associated with asthma in adolescence and adulthood in hospitalized 
bronchiolitis patients. 
 
 
1Odds ratio and 95% Confidence interval, 2 NS, Not significant, OR or p-value not available, 
3Adjusted with history of RSV bronchiolitis, parental asthma and atopy, 4Multivariate analysis with 
female gender, maternal smoking during pregnancy, RSV infection at first admission, furry pets at 
home in infancy, start of wheezing before the age of 6 months and intense obstructive disease as a 
young child included, 5Adjusted with current allergy and active smoking, 6Serum allergen-specific 
immunoglobulin (IgE) >0.35kU/l, 7Adjusted with RSV etiology of bronchiolitis, and parental asthma, 
8Adjusted with sex and age, 9Multivariate analysis with family atopy and female gender included in 
analysis, 10Adjusted with age, sex, smoking, allergic rhinitis, asthma in parents, asthma in siblings, 
11Adjusted with atopy at the age if 18-20 years, 12Compared to population controls, 13Compared to 
RSV bronchiolitis patients, 14Adjusted with sex, age on admission, current smoking and atopy 
Risk factor Age (yrs) at the time of asthma diagnosis OR (95%CI)
1 Reference 
Wheezing history    
Recurrent wheezing < 2 years 18-20 5.35 (1.03 – 27.82) Piippo-Savolainen 2006 
 
26-29 NS.2 Ruotsalainen 2010 
Inheritance 
   
Parental asthma 18-20 16.11 (1.66 – 156.46) Piippo-Savolainen 2006 
 13 4.7 (1.6 – 13.9)3 Sigurs 2005 
 
27 4.0 (1.3–12.5) 4 Goksör 2014 
Host factors 
   
Female gender 27 3.2 (1.1–9.3)5 Goksör 2014 
Atopy < 2 years 18-20 4.43 (1.29 – 15.2) Piippo-Savolainen 2006 
 26-29 NS. 2 Ruotsalainen 2010 
Sensitization to pollens < 3 years6 13.5 - 16 7.99 (1.09 – 58.52)7 Piippo-Savolainen 2008 
Eosinophilia (>0.45x10E9/l)8 15-18 21.30 (1.06 – 426.42) Ruotsalainen 2009 
 26-29 NS. 2 Ruotsalainen 2010 
Environmental factors    
Maternal smoking during pregnancy 17-20 3.5 (1.1 – 11.3)9 Goksör 2007 
Passive smoking in infancy 17-20 3.4 (1.2 – 10.1)9 Goksör 2007 
RSV etiology 15-18 11.63 (1.71) 10 Ruotsalainen 2012 
 18-20 1.40 (0.36 – 5.35)11 Korppi  2004 
 26-29 12 11.4 (2.95 – 44.05) Ruotsalainen 2010 
Non-RSV etiology 15-18 11.49 (3.88 – 34.00)10 Ruotsalainen 2012 
 18-2013 8.34 (1.18 – 58.69)14 Piippo-Savolainen 2007 
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2.4.8 Frequency of wheezing symptoms 
Recurrent wheezing symptoms after early childhood bronchiolitis are common (Korppi et al. 
1993, Reijonen et al. 2000). It has previously been demonstrated that afterhospitalized 
bronchiolitis more than 2 wheezing episodes during the first 2 years of life increased the 
likelihood of asthma in adolescence and adulthood (Hyvarinen et al. 2005, Piippo-Savolainen et 
al. 2006). In more recent studies, school-age asthma was associated with the frequency of 
wheezing episodes (Pescatore et al. 2014, Bacharier et al. 2012) or the frequency of troublesome 
respiratory symptoms (Bonnelykke et al. 2015) in children less than 3 years of age.  
 
2.4.9 Early lung function 
Several studies have demonstrated the association between diminished infantile lung function 
and subsequent tendency for wheezing in early childhood (Martinez et al. 1991, Young et al. 
2000, Dezateux et al. 1999, Murray et al. 2002). In a similar manner, decreased lung function 
soon after birth is associated with an increased risk for asthma in childhood (Bisgaard et al. 
2012, Lodrup Carlsen et al. 2014), adolescence (Lodrup Carlsen et al. 2014) and adulthood 
(Mullane et al. 2013). In addition, bronchial hyperreactivity at the age of 12 months has also 
been associated with an increased risk for asthma in childhood (Turner et al. 2009). These 
findings suggest that lung function deficits found in asthma patients are at least partly 
congenital (Guerra & Martinez 2009).  
 
2.4.10 Predicting the persistence of wheezing symptoms 
The recurrence of wheezing symtoms in early childhood predicts asthma in later life. In the 
present cohort, recurrent symptoms were a significant risk factor for later asthma still between 
the ages of 18-20 years after bronchiolitis but not after that (Piippo-Savolainen et al. 2006, 
Ruotsalainen et al. 2010a) (Table 1). However, not all children who have wheezing before the 
age of 3 years develop persistent symptoms and eventually asthma. In fact, the majority of them 
are asymptomatic by the age of 6 years and can be classified as transient wheezers (Martinez et 
al. 1995). It is difficult to distinguish transient wheezers and those with more persistent type of 
wheezing in early childhood. Therefore, predicting the persistence of wheezing symptoms and 
the development of later asthma in children with early childhood wheezing symptoms has been 
a challenge. 
 In 2000, the Tucson group presented the asthma predictive index (API), which 
predicts asthma up to the age of 13 years in young children with recurrent wheezing (Castro-
Rodriguez et al. 2000) (Table 3). A stringent index includes frequent wheezing during the first 3 
years of life and either one of the major risk factors, parental history of asthma or eczema in 
child, or two of three minor risk factors, which are the presence of eosinophilia, wheezing 
without colds, and allergic rhinitis in child (Table 2). The lenient index requires any wheezing 
during the first 3 years of life plus the same combination of risk factors as the stringent index 
(Castro-Rodriguez et al. 2000). A positive stringent API score by the age of 3 years is associated 
with a 77% chance of active asthma between the ages of 6–13 years (Castro-Rodriguez et al. 
2000). However, children with a negative API score at the age of 3 years have less than a 3% 
chance of developing active asthma during their school years and can be classified as transient 
wheezers (Castro-Rodriguez 2011). Modification of API (mAPI) has been proposed (Guilbert et 
al. 2004b, Guilbert et al. 2004a) and tested recently in the Childhood Origins of Asthma 
(COAST) cohort (Chang et al. 2013). Regarding mAPI, sensitization to at least one aeroallergen 
was proposed as an additional major criterion and allergic sensitization to milk, egg, or peanuts 
as a minor criterion instead of allergic rhinitis (Chang et al. 2013). However, it has been argued 
that the determination of sensitization is expensive and unreliable, since allergens vary in 
different populations (Castro-Rodriguez 2011). 
 The Isle of Wight score, described in 2003, identified risk factors to predict the 
persistence of wheezing in early childhood wheezers (Kurukulaaratchy et al. 2003). The score 
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has four criteria, including family history of asthma, recurrent chest infections in the second 
year of life, atopic sensitization at 4 years of age, and the absence of recurrent nasal symptoms 
in the first year of life. 
 The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) risk score was 
developed in 2009 to predict asthma up to the age of 8 years (Caudri et al. 2009) and updated 
later (Hafkamp-de Groen et al. 2013). In addition to atopic characteristics that are also described 
in other asthma predictive scores, it also includes male sex, preterm birth, and parental 
education. 
 In 2008, the Korppi group presented a modified asthma predictive index for 
children hospitalized for bronchiolitis based on findings of the Finnish and Swedish post-
bronchiolitis cohorts (Piippo-Savolainen & Korppi 2008) (Table 3). As in the Tucson API, the 
risk factors were classified as major or minor factors. This is so far the only predictive algorithm 
that takes viral etiology of wheezing illness into account. However, this index has not been 
validated, and its predictive value is not known. 
 Of these indices, API is probably the most well known and the easiest to use in a 
clinical setting. The asthma predictive index of the Korppi group includes factors that are 
known to be risk factors for adult asthma in hospitalized bronchiolitis patents. However, all 
these indices share low sensitivity but fairly good negative predictive value to identify children 
with probable transient wheezing (Castro-Rodriguez 2011). Parental history of asthma and 
features of atopic disease in children seem to be common features in predicting the future risk 
for asthma. However, these indices predict asthma only up to the school age, since follow-up up 
to the adult age is not included in any of these indices.   
As a conclusion, it seems that in long-term follow-up studies, the early risk factors 
for asthma seem to lose their significance in adulthood. In a 27-year follow-up of Finnish post-
bronchiolitis cohort, significant early life risk factors could not be identified (Ruotsalainen et al. 
2010a), and in a Swedish follow-up at the same age, only female gender and parental asthma 
predicted the persistence of asthma up to adulthood (Goksor et al. 2015). This may be due to 
numerous disease modifying factors and new risk factors that weaken and modify the effect of 
early risk factors in the development of adulthood asthma (Ruotsalainen et al. 2010a). 
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Table 3. Asthma predictive indices in children with early childhood wheezing 
 
Asthma predictive index (API)1 
≥3 wheezing episodes before the age of 3 years and one major or two minor criteria required for positive index 
Major Criteria  
Physician diagnosis of parental asthma  
Physician diagnosis of atopic dermatitis in child  
Minor Criteria  
Physician diagnosis of allergic rhinitis  
Wheezing apart from colds  
Eosinophilia (≥4%)  
  
Isle of Wight score2 
Wheeze ever before the age of 4 years required. Scoring 4 risk factors was associated with symptom persistence in 
83% up to the age of 10 years. 
Criteria  
Recurrent chest infections at 2 yrs  
Family history of asthma  
Atopic SPT at 4 yrs  
Nasal symptoms at 1 yr  
 
PIAMA risk score3 
Wheeze ever before the age of 4 years required. Risk of asthma when total score 0-7 <5%, 8-15 6%-22%, 16-23 
25%-60%, maximum 23 points. 
Risk score  
Male sex 2 
Medium/low parental education 1 
Parental asthma 4 
preterm delivery <37 weeks 1 
Wheezing frequency  
1-3 times/y 4 
4 times/y 7 
Wheezing/dyspnea apart from colds 2 
Doctor’s diagnosis of eczema 6 
 
Asthma predictive index for children hospitalized for bronchiolitis4 
Hospitalization for bronchiolitis in infancy and one major or two minor criteria required for positive index 
Major Criteria  
Physician diagnosis of parental asthma  
Physician diagnosis of atopic dermatitis or food allergy in child  
Parental, especially maternal, smoking  
Minor Criteria  
Sensitization to inhaled allergens  
Wheezing induced by other viruses than RSV  
Blood eosinophilia or lack of eosinopenic response during viral infection  
1Castro-Rodriguez 2000, 2Kurukulaaratchy 2003, 3Hafkamp 2013, 4Piippo-Savolainen 2008 
24 
 
 
2.5 LUNG FUNCTION AFTER EARLY CHILDHOOD WHEEZING 
2.5.1 Early childhood lung function and LRTI´s 
Several retrospective studies and post-bronchiolitis studies have demonstrated the association 
between early childhood respiratory infections, lung function reduction, and respiratory 
morbidity in adulthood (de Marco et al. 2011, Piippo-Savolainen et al. 2004, Sigurs et al. 2010, 
Goksor et al. 2008, Barker et al. 1991). However, these studies have been unable to answer the 
question of whether or not the impairment of lung function is a consequence of respiratory 
infections in early childhood.  
The Tucson birth cohort study was the first study to attempt to answer this 
question. In this cohort, lung function was measured in early childhood before any respiratory 
infections. It became evident that infants who have respiratory illnesses with wheezing  during 
the first year of life have lower levels of lung function before any lower respiratory illness 
develops than non-symptomatic infants (Martinez et al. 1995, Martinez et al. 1988). Later, 
several birth cohorts have verified this finding (Tager et al. 1993, Dezateux et al. 1999, Murray et 
al. 2002, Young et al. 1991). In addition, it has been demonstrated that bronchial hyperreactivity 
in early infancy is a specific finding that also predicts increased hyperreactivity and is strongly 
associated with asthma later in childhood (Turner et al. 2009). In line with this, neonatal 
bronchial hyperreactivity has been demonstrated to increase the risk of acute severe 
bronchiolitis (Chawes et al. 2012). According to these results it seems that neonatal bronchial 
hyperreactivity is a pre-existing state, predisposing infants to later development of both acute 
viral bronchiolitis and childhood asthma (Bisgaard et al. 2012, Chawes et al. 2012). According to 
their results, it may be justified to conclude that the association between early airway 
impairment and subsequent development of LRTIs during the first years of life has been 
established (Martinez 2002). 
Even though most children who have wheezing during respiratory infections in 
early childhood grow out of this tendency, transient wheezers have also been described to have 
impaired lung function before any respiratory infections. In the Tucson birth cohort study, the 
level of lung function did not seem to improve with inceasing age, and lung function 
impairment was still present at the age of 6 years (Martinez et al. 1995) and even at the age of 22 
years (Stern et al. 2007). So, it seems evident that, at least partly, early childhood wheezing 
reflects congenitally small airways and predisposes children to wheezing during respiratory 
illness at early age (Martinez et al. 1995) and to lung function impairment up to adult age (Stern 
et al. 2007). Due to these findings, it has been speculated that even transient early wheezers may 
have increased risk for COPD as they get older (Taussig et al. 2003). However, the Australian 
birth cohort study was not able to confirm these findings, since low lung function soon after 
birth associated only with persistent wheezing phenotype at the age of 18 years (Mullane et al. 
2013). 
Despite these convincing results, lung function at birth is not the only determinant 
of later respiratory morbidity. A Danish birth cohort study demonstrated that 14% of children 
with asthma by age 7 already had a significant airflow deficit as neonates (Bisgaard et al. 2012). 
However, this deficit progressed significantly during early childhood, and it was concluded 
that approximately 40% of the airflow deficit associated with asthma at the age of seven is 
present at birth, whereas 60% develops with clinical disease (Bisgaard et al. 2012). 
Environmental tobacco exposure also hampered lung function development in childhood 
(Bisgaard et al. 2012). As a conclusion, it seems that even if part of the lung function is 
determined before birth or very soon after that, the lung development can be influenced by 
various factors also in later life. 
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2.5.2 Risk factors for early lung function impairment 
There are numerous factors that may hamper lung growth during pregnancy or during the 
rapid growth of the lungs in early childhood. These factors may prevent the lungs to acquire the 
full pulmonary potential, and can alone or together with later environmental factors predispose 
subjects to respiratory morbidity such as asthma and even COPD in the future (Postma et al. 
2015, Stocks et al. 2013). 
Intrauterine growth retardation (Canoy et al. 2007) and preterm delivery (Kotecha 
et al. 2013) result in decreased alveolar number and surface area and, as a result, reduced lung 
function at birth and later in life. 
 Maternal smoking during pregnancy is evidently the most important preventable 
factor associated with lung function impairment in utero (Martinez et al. 1988, Tager et al. 1993, 
Landau 2008, Lodrup Carlsen et al. 1997, Bisgaard et al. 2009, Murray et al. 1992). Significant 
suppression of alveolarization, functional residual capacity, and tidal flow volume have been 
demonstrated in children with prenatal smoke exposure (Rehan et al. 2009). In addition, the 
inverse dose-response relationship of smoked cigarettes during pregnancy and tidal flow-
volume ratios in healthy newborn babies was demonstrated in a Norwegian birth cohort 
(Lodrup Carlsen et al. 1997). It was demonstrated later in the same cohort that low lung 
function measured at birth as well as maternal daily smoking during pregnancy are 
independent risk factors for developing obstructive airway disease within the first 2 years of life 
(Lodrup Carlsen et al. 1999). In addition to lung function impairment at birth, maternal 
smoking during pregnancy has been associated with poor lung function up to early adulthood 
(Stern et al. 2007). 
Decreased airway conductance, determined from plethysmographic measurements 
of lung volume and airway resistance, has been described to be present in early infancy in 
relation to familial asthma (Dezateux et al. 1999). Parental asthma is also a risk factor for 
bronchial hyperreactivity to histamine in small babies, suggesting a significant role of heredity 
with regards bronchial hyperreactivity at early age (Martinez et al. 1988, Young et al. 1991).  
 
2.5.3 Viral infections and the lungs 
It has been established in epidemiological studies that early childhood LRTI leads to impaired 
lung function later in life (de Marco et al. 2011, Piippo-Savolainen et al. 2004, Sigurs et al. 2010, 
Goksor et al. 2008, Barker et al. 1991). However, it has been proposed that low lung function 
after LRTI might instead result from adverse events during the prenatal period (Martinez et al. 
1995, Martinez et al. 1988, Tager et al. 1993, Dezateux et al. 1999, Murray et al. 2002, Young et al. 
1991, Rossi & Colin 2015). However, experimental studies based on animal models have 
demonstrated that respiratory viruses can also directly damage developing lungs at an early 
age (Rossi & Colin 2015). 
During RSV infection, viral antigen recognition induces the production of a variety 
of pro-inflammatory mediators, such as tumor necrosis factor alfa, eotaxins, interleukins and 
chemokines. These activate the innate and adaptive immune responses to limit viral infection 
(McNamara et al. 2004, McNamara et al. 2005, McNamara et al. 2004). Pro-inflammatory 
mediators induce monocyte and polymorphonuclear cell influx in the airways to enhance the 
cytopathic effect of RSV and to misdirect the immune response (Rossi & Colin 2015, Bem et al. 
2011). It has also been demonstrated that RSV infection causes neurogenic inflammatory 
reactions that activate cholinergic and excitatory noncholinergic, nonadrenergic neural 
pathways, resulting in a predisposition for airway obstruction and airway hyperreactivity 
(Rossi & Colin 2015, Jafri et al. 2004, You et al. 2006).  
 In the absence of other contributing factors, primary RSV infection does not usually 
lead to marked eosinophilia in the lungs (Becnel et al. 2005, Bem et al. 2011, Johnson et al. 2007). 
However, early allergic sensitization or very early primary infection can lead to aberrant 
immune responses following RSV infection that have long lasting affects on the lungs (Becnel et 
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al. 2005, Johnson et al. 2007). More specifically, it has been demonstrated that bronchial 
hyperreactivity, increased eosinophil and lymphocyte cell numbers, enhanced mucus 
production and signs of airway remodeling, including subepithelial fibrosis, were present in 
young mice after RSV infection when combined with allergic sensitization prior to infection 
(Becnel et al. 2005). Subsequent work demonstrated the relationship between early-life viral 
infections and allergen sensitization in the development of a TH2-biased immune response and 
allergic inflammation in the lungs (You et al. 2006, Siegle et al. 2010). Based on these findings, it 
has been suggested that allergic inflammation can potentiate the effect of RSV infection on the 
developing lung, leading to the development of chronic asthma (You et al. 2006, Becnel et al. 
2005). In addition, the timing of the primary RSV infection seems to be a crucial factor in 
determining the outcome of reinfection later in life (Culley et al. 2002, Dakhama et al. 2005). 
Developing immune systems in neonates tend to display prolonged TH2-biased immune 
responses to RSV instead of more immunologically mature TH1-responses (Culley et al. 2002). It 
has been demonstrated that infected neonatal mice results in the production of severe 
inflammatory responses, lung eosinophilia, mucus and bronchial hyperreactivity during RSV 
reinfection. In contrast, later primary infection protects against the development of these altered 
airway responses during the reinfection (Culley et al. 2002, Dakhama et al. 2005).  
A similar association has also been found between age at the time of the HRV 
infection and outcome after the infection (Schneider et al. 2012, Hong et al. 2014). HRV infection 
in neonatal mice, unlike infection in mature mice, induced TH2-biased immune responses, 
airway hyperresponsiveness and mucous metaplasia (Schneider et al. 2012, Hong et al. 2014). 
Thus, it seems that TH2-biased immune responses early in life can provide a favorable 
environment for asthma development, particularly when maintained by appropriate stimuli 
like viral infections (Schneider et al. 2012, Hong et al. 2014). 
   
2.5.4 Lung function after early childhood LRTI 
Impaired lung function (Sigurs et al. 2005, Hyvarinen et al. 2007) and increased bronchial 
responsiveness (Kotaniemi-Syrjanen et al. 2008, Wennergren et al. 1997) in childhood have been 
demonstrated to be present after early childhood bronchiolitis. In addition, it has been 
demonstrated that after bronchiolitis in infancy, lung function may remain reduced until early 
adulthood (Piippo-Savolainen et al. 2004, Sigurs et al. 2010, Goksor et al. 2008). In a Swedish 
post-RSV bronchiolitis cohort, a reduced FEV1/FVC ratio was present before and after 
bronchodilatation at the ages of 13 and 18 years despite the increased reactivity in airways 
(Sigurs et al. 2010, Sigurs et al. 2005). In line with a RSV bronchiolitis cohort, 17-20 year follow-
up of Swedish post-bronchiolitis cohort revealed that FEV1/FVC and MEF50 were reduced 
before and after bronchodilatation. As a conclusion, findings from these two cohorts indicated 
signs of irreversible airway obstruction after bronchiolitis (Sigurs et al. 2010, Goksor et al. 2008). 
It was also demonstrated in a Swedish post-bronhiolitis cohort that lung function reduction is 
present in symptom-free study subjects who had lower levels of lung function compared to 
symptom-free controls, which corroborates the results of the 22-year follow-up of the Tucson 
birth cohort study (Goksor et al. 2008, Stern et al. 2007).  
Factors associated with lung function impairment or bronchial hyperreactivity after 
early childhood wheezing have included female gender (Kotaniemi-Syrjanen et al. 2008, Goksor 
et al. 2008), prenatal smoke exposure (Goksor et al. 2007, Hyvarinen et al. 2007), parental 
smoking (Piippo-Savolainen et al. 2006), and early atopy (Hyvarinen et al. 2007). Rhinovirus 
etiology of bronchiolitis, however, has been associated with increased bronchial responsiveness 
in a Finnish viral bronchiolitis cohort (Kotaniemi-Syrjanen et al. 2008). However, the later 
follow-up of the same cohort at the age of 11 years revealed a more restrictive type of lung 
function impairment after RSV bronchiolitis (Hyvarinen et al. 2007). 
 Lung function after early childhood pneumonia has not been studied with the 
intensity of post-bronchiolitis lung function. However, in the Tucson birth cohort study, 
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radiologically confirmed pneumonia at less than 3 years of age was associated with reduced 
lung function at the age of 6 and 11 years compared to those with no respiratory infections at  
early age (Castro-Rodriguez et al. 1999). Pneumonia patients also had similar premorbid 
changes in lung function than bronchiolitis patients (Taussig et al. 2003). In addition, a recent 
systematic review concluded that restrictive pulmonary disease is the most common sequela 
after pneumonia in early childhood (Edmond et al. 2012). However, two historical birth cohorts 
found more obstructive patterns of lung function reduction with reduced FVC and FEV1 in late 
adulthood in those with history of early childhood pneumonia (Barker et al. 1991, Shaheen et al. 
1998). In addition, in a recent follow-up of the Tucson cohort, reduced FEV1/FVC was 
demonstrated at the age of 26 years in those with a history of early childhood pneumonia (Chan 
et al. 2015). These findings suggest that pneumonia and bronchiolitis may share the same 
predisposing factors and that these diseases are in the same spectrum of viral respiratory 
infections (Taussig et al. 2003). 
 It is still unclear whether early childhood LRTIs such as bronchiolitis and 
pneumonia cause further impairment of lung function in young children. In the Australian birth 
cohort study, reduced lung function was present before and after bronchiolitis at the age of 11 
years, and the level of reduction was comparable (Turner et al. 2002). It was concluded that the 
mechanism for wheeze and reduced lung function after bronchiolitis appears to be related to 
state of premorbid lung function, not to bronchiolitis (Turner et al. 2002). However, there is 
clear evidence that RSV causes damage to airways that leads to bronchial hyperreactivity, 
peribronchial and perivascular inflammation, and subepithelial fibrosis several months after 
initial infection in mice (Jafri et al. 2004, You et al. 2006).   
It has been established that impaired lung function occurs after early childhood 
LRTI. Results of several birth cohort studies suggest that impaired lung function is associated 
with premorbid low infantile lung function rather than the consequence of viral infection. 
However, recent data have demonstrated that viral infections cause direct damage to the lungs 
that can result in long-term consequences for bronchial hypereactivity and airway remodelling. 
These findings suggest that both theories may be true. 
2.6 HEALTH-RELATED QUALITY OF LIFE AFTER EARLY CHILDHOOD LRTI 
2.6.1 Health-related quality of life, wheezing and asthma 
The WHO defines 'quality of life' as an individual´s perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards, and concerns (The World Health Organization Quality of Life 
Instruments 1997). The emphasis in medicine has changed from acute diseases to prevention 
and control of chronic conditions. As a result, the measurement of health-related quality of life 
is becoming an increasingly important method to assess health outcome measurement in 
medical studies (Eiser & Morse 2001, Rutishauser et al. 1998). Various questionnaires have been 
developed to measure quality of life in children and adolescents with asthma and asthma-
related symptoms (Rutishauser et al. 1998, Rutishauser et al. 2001) and adults with asthma or 
COPD (Wilson et al. 2012, Weldam et al. 2013). 
 Asthma and wheezing have been associated with reduced health-related quality of 
life (HRQoL) in childhood (Covaciu et al. 2013, Beattie & Lewis-Jones 2006, Oostenbrink et al. 
2006, Cui et al. 2015) and adulthood (Adams et al. 2001). At the 8-year follow-up of the Swedish 
Bamse birth cohort, HRQoL was assessed by parents completing the standard HRQoL 
instrument EQ-5D. They found that allergic diseases such as asthma, rhinitis, atopic eczema, 
and food hypersensitivity were all associated with reduced HRQoL at the age of 8 years. Study 
subjects with asthma had the lowest HRQoL scores (Covaciu et al. 2013). Asthma-like 
symptoms during the first year of life have also been associated with impaired HRQoL at the 
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age of 12 months. In addition, wheezing attacks during the past 12 months have also been 
associated with reduced HRQoL in adolescents (Mohangoo et al. 2007, Mohangoo et al. 2012).  
 
2.6.2 Health-related quality of life after LRTI 
There are not many studies about the association between early bronchiolitis or pneumonia and 
subsequent HRQoL after these diseases. A recent Norwegian study enrolled 209 infants that 
had been hospitalized for bronchiolitis and 206 controls at a mean age of 4 months (Rolfsjord et 
al. 2015). Quality of life was studied with Infant Toddler Quality of Life Questionnaire (ITQOL) 
9 months later. Infants with a history of bronchiolitis had lower quality of life scores compared 
to controls in the overall health and general health domains of the questionnaire (Rolfsjord et al. 
2015). A very similar pattern of HRQoL impairment was found in another study that also used 
ITQOL 2-6 months after RSV bronchiolitis (Spuijbroek et al. 2011). In addition to these studies, 
impaired HRQoL attributed to post-bronchiolitis wheezing has been described in children 3 
years after hospitalization for RSV bronchiolitis (Bont et al. 2004). However, there are no 
previous studies on quality of life after early childhood bronchiolitis, including follow-ups 
longer than three years. 
 In the child population, CAP has been described to affect HRQoL in the short term 
(Shoham et al. 2005). In the adult population, the recovery of respiratory symptoms after CAP is 
fast, but the recovery of general HRQoL to premorbid levels has been described to take 6-18 
months (El Moussaoui et al. 2006). There are no studies that would had provided information 
about the long-term outcome of early childhood pneumonia with regards to HRQoL. 
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3 Aims of the study 
The aim of the present study was to evaluate respiratory morbidity, health-related quality of 
life, and lung function in adulthood in study subjects who were hospitalized for bronchiolitis or 
pneumonia at ages less than 2 years. The connection of RSV etiology of LRTI in infancy with 
these outcomes was studied. In addition early childhood risk or protective factors for asthma 
and lung function reduction in adulthood were investigated. 
 
The specific aims of the study were as follows: 
 
Evaluate if the prevalence of asthma is increased in adulthood after bronchiolitis or pneumonia 
in early childhood when compared to population controls; 
 
Study if reduced lung function and irreversible bronchial obstruction are present between the 
ages of 28-31 years after bronchiolitis or pneumonia in early childhood; 
 
Describe the respiratory health-related quality of life in adulthood after bronchiolitis or 
pneumonia in early childhood; 
 
Examine the impact of RSV etiology on the adulthood outcome of ealy childhood LRTI 
hospitalization; 
  
Clarify the role of early-childhood risk or protective factors for asthma and lung function 
reduction in adults 30 years after bronchiolitis in infancy; 
 
Examine the role of blood eosinophil count during early childhood bronchiolitis or outside the 
infection as a determinant for subsequent respiratory morbidity in adulthood. 
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4 Subjects and Methods 
4.1 STUDY DESING AND ENROLLMENT OF STUDY SUBJECTS IN 1981-1982 
4.1.1 Enrollment of study subjects 
Between 1 September 1981 and 31 August 1982, 130 children who were hospitalized for LRTI in 
Kuopio University Hospital Department of Pediatrics at the age of less than 2 years were 
enrolled in the study (Korppi et al. 1986). Three children were excluded before the analysis due 
to inappropriate collection of early childhood data. Among the 127 recruited children (77 boys 
and 50 girls) with LRTI, 83 of them had bronchiolitis and 44 had pneumonia.Most (75%) of the 
children with diagnosed bronchiolitis were wheezing for the first time. Bronchiolitis was 
diagnosed based on the auscultatory findings of prolonged expiratory phase and expiratory 
wheezing. Chest radiographs were obtained in all cases, and pneumonia was diagnosed in 
study subjects who presented viral LRTI without wheezing but had an interstitial infiltration on 
chest radiograph. None of the pneumonia patients had large alveolar infiltrates that are 
characteristic for Streptococcus pneumoniae pneumonia. Those study subjects who presented an 
interstitial infiltration on the chest radiograph and had expiratory breathing difficulties (n=46) 
were included in bronchiolitis group (Korppi et al. 1986). 
4.1.2 Viral etiology 
The viral etiology of LRTI was determined with antigen assays from nasopharyngeal aspirates 
(NPA) and with abtibody assays from paired serum samples for 7 respiratory viruses, including 
RSV, parainfluenza 1, 2 or 3 viruses, adenovirus, and influenza A and B viruses (Korppi et al. 
1986). The RSV antigen or antibody test was positive in 51/127 (40%) children (Korppi et al. 
1986). In addition, 30 children who were RSV negative (and negative for the other six studied 
viruses) were hospitalized during the severe nationwide RSV epidemic between 1 October and 
31 December 1981. Thus, 81/127 (64%) of the children either had a confirmed RSV infection or a 
highly probable RSV infection due to the susceptible age, typical clinical presentation, and 
community epidemic.  
4.2 COLLECTION OF DATA UNTIL THE AGE OF 2-3 YEARS 
4.2.1 Follow-up visits in early childhood 
After the index LRTI episode, 4 prospective follow-up studies were conducted to collect the 
early childhood data: one on convalescence, 4-6 weeks after hospitalization, 2 between the ages 
1-2, and one between the ages of 2.5-3 years (Figure 1). Collected data included doctor-
diagnosed asthma and allergy in mothers and fathers, parental smoking history, and the 
presence of doctor-diagnosed atopic dermatitis in children at less than 2 years of age. The 
number of wheezing episodes was registered separately for the age periods of 0-1 years and 1-2 
years. Doctor-diagnosed, repeated wheezing was defined by more than 2 wheezing episodes 
during the year preceding the control visit. 
 Serum allergen-specific IgE (RAST, Pharmacia Diagnostica, Uppsala, Sweden) was 
measured in 67 children between 1.5-2 years of age and in 76 children between 2.5-3 years of 
age (Piippo-Savolainen et al. 2007b). The studied allergens were birch, timothy grass and 
mugwort pollens, house dust mite Dermatophagoides pteronyssinus, spores of Cladosporium 
herbarum, and dander of cat and dog. Total serum IgE was studied at the age of 6-12 months and 
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at the age of 18-24 months. Atopy in infancy was originally defined as the presence of doctor-
diagnosed atopic eczema and/or high total serum IgE (>60kU/l) at the age of less than 2 years 
(Reijonen & Korppi 1998, Piippo-Savolainen et al. 2007a, Saarinen et al. 1982). Atopic 
sensitization was defined as the presence of specific IgE to any allergen at the detection level 
>0.35 kU/l. 
Blood eosinophils were counted on admission and on convalescence 4-6 weeks 
after admission to hospital. The cut-off limit was >0.45x10E9/l for high blood eosinophil count 
and <0.25x10E9/l for low blood eosinophil count (Reijonen & Korppi 1998, Piippo-Savolainen et 
al. 2007a). 
4.3 FOLLOW-UP IN CHILDHOOD, ADOLESCENCE, AND EARLY ADULTHOOD 
4.3.1 Study subjects  
Between the ages of 4.5-6 years, when pneumonia cases were not invited, 68/83 former 
bronchiolitis patients attended the clinical study. Between the ages of 8-9.5 years, 91 study 
subjects (62/83 from bronchiolitis and 29/44 from pneumonia group) were clinically examined. 
At the age of 13.5-16 years, 98/127 (77%) former bronchiolitis and pneumonia patients attended 
the questionnaire study. In 2000, 54/83 former bronchiolitis and 34/44 pneumonia patients 
attended the clinical follow-up study (Figure 1). On each follow-up visit, allergy and asthma 
were carefully screened. Skin prick tests (SPT) were performed betwen the ages of 8-10 years 
and 18-20 years including the most common inhaled allergens (Piippo-Savolainen et al. 2004, 
Korppi et al. 1994). Flow volume spirometry (FVS) was conducted at the age periods of 8-10 
years and 18-20 years (Piippo-Savolainen et al. 2004, Korppi et al. 1994).  
The control group was not originally enrolled in the study. However, at the age 
periods of 8-10, 18-20, and 26-29 years, controls were recruited from an atopy prevention study 
(Figure 1) (Piippo-Savolainen et al. 2004, Korppi et al. 1994, Ruotsalainen et al. 2010a, Poysa et 
al. 1988). At the 26-29 years follow-up, population-based controls were recruited for the first 
time (Ruotsalainen et al. 2010a).  
4.4 FOLLOW-UP STUDY IN 2010 
4.4.1 Study subjects 
In 2010, at the age period of 28-31 years, a written questionnaire and an invitation to the clinical 
study was sent to 122 of the 127 study subjects. The current addresses of the five other study 
subjects were unavailable. Sixty (72%) of the 83 subjects from the bronchiolitis and 24 (55%) of 
the 44 subjects from the pneumonia group returned the questionnaire. Forty-eight (58%) and 22 
(50%) study subjects, respectively, attended the clinical study.  
 The RSV LRTI group consisted of 43 clinically examined study subjects, including 
27 former bronchiolitis and 16 former pneumonia patients. Out of them, 24 subjects had 
confirmed RSV infection during LRTI in infancy, and 19 had highly probable RSV infection (i.e., 
hospitalized during the epidemic with identical clinical pictures as the confirmed RSV cases) in 
infancy. 
 
4.4.2 Controls 
For the 2010 follow-up, 488 population-based control subjects were enrolled at a 4:1 ratio for the 
122 cases from the Population Register Centre in Finland. Controls were born in the primary 
area near the Kuopio University Hospital, and they were matched for sex and birth month.  
Four control subjects who had been treated in the hospital for lower airway infection at less 
than 24 months of age were excluded.  In total, 166 (34%) control subjects returned the 
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completed questionnaire, and 138 (28%) attended the clinical study. For 43 RSV positive study 
subjects, a control group of 86 (2 controls for each study subject) was constructed by using sex 
and birth date as the selection criteria. 
 
Figure 1. Flow chart showing the follow-up of the 1980’s Finnish post-bronchiolitis and pneumonia 
study from early childhood up to the age of 28-31 years. 
 
Control visit 4-6 weeks after the
hospitalization1
2 control visits at the age of 1.5 – 2 
years2
Enrollment at the hospitalization
before the age of 2 years1
Clinical follow-up at the age of 8-10 
years4
Clinical follow-up at the age of 4.5 -
6 years3
Clinical follow-up at the age of 2.5 –
3 years2
Clinical follow-up at the age of 18-
20 years6
Postal questionnaire at the age of 
13.5-16 years5
Clinical follow-up at the age of 28-
31 years8
Postal questionnaire at the age of 
26-29 years7
83 Bronchiolitis
patients
3 excluded before
the analysis
47 Pneumonia 
patients
138 Population
Controls
105 Population
Controls
54 Selected controls
39 Selected controls
N = 34N = 76
N = 48
N = 59
N = 65
N = 54
N = 62
N = 68
N = 34
N = 33
N = 29
N = 22
N = 26
52 Selected controls
 
 
References: 1Korppi  1986, 2Korppi 1993, 3Kuikka 1994, 4Korppi 1994, 5Hyvärinen 2005, 6Piippo-
Savolainen 2004, 7Ruotsalainen 2010, 8Backman 2014 
 
4.4.3 Questionnaire data 
The questionnaire comprised of questions on asthma-presumptive symptoms such as wheezing, 
repeated night cough, or prolonged day cough apart from infection during the preceding 12 
months. In addition, the questionnaire also included inquiries about the presence of previous 
doctor-diagnosed asthma and the regular use of inhaled corticosteroids (ICS) or on-demand use 
of bronchodilators during the preceding 12 months. The occurrence of presumptively allergic 
nasal, eye, and skin symptoms were charted for the preceding 12 months. 
 Current and previous smoking status was determined. Study subjects were 
considered to be current daily smokers if they smoked at the time of the study and had smoked 
at least one cigarette per day for one year. Pack-years were calculated for current and earlier 
smokers if they had smoked daily at least for one year using the following equation: the number 
of cigarettes smoked daily multiplied by smoking years and divided by 20 (Forey et al. 2011).  
 
4.4.4   Respiratory health-related quality of life 
The participants completed the St. George’s Respiratory Questionnaire (SGRQ), a widely used 
self-administered questionnaire designed to measure health impairment and respiratory health-
related quality of life in adults with asthma or COPD (Jones et al. 1991, Jones et al. 1992).  
 Three different component scores can be calculated from the SGRQ: the symptom 
component (the level of respiratory symptoms based on their frequency and severity), the 
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activity component (the activities that cause breathlessness or the activities in which 
participation is limited due to breathlessness), and the impact component (social or 
psychological disturbances resulting from airway disease). The total score summarizes the 
influence of the disease on the overall respiratory health-related quality of life of the participant. 
The scores are expressed as a percentage of complete impairment; thus, the score 100 
represents the worst possible respiratory health status, and the score 0 represents the best 
possible respiratory health status (Jones et al. 1991, Jones et al. 1992). 
 
4.4.5 Clinical study 
The clinical study consisted of an interview, physical examination, exhaled Nitric Oxide (FeNO) 
measurement, lung function test with bronchodilatation, SPTs for common inhaled allergens, 
and two-week home peak expiratory flow (PEF) monitoring. 
 
4.4.6 Exhaled nitric oxide measurement 
Orally exhaled nitric oxide (FENO) was measured with a NIOX MINO Airway Inflammation 
Monitor (Aerocrine AB, Solna, Sweden) according to the ATS and ERS standards (American 
Thoracic Society & European Respiratory Society 2005). At minimum, two measurements were 
required, and inhalations were repeated until two values were obtained within 10% of each 
other. Acceptable FENO was obtained from all but one of the study subjects and from all controls. 
 
4.4.7 Flow volume spirometry and the definition of irreversible airway obstruction 
Baseline lung function was measured with a Medikro SpiroStar USB spirometer (Medikro, 
Kuopio, Finland) using Spiro 2000, Software version 2.2. FVS was performed, and the results 
were reported according to ATS (American Thoracic Society) and ERS (European Respiratory 
Society) standards (Miller et al. 2005). At a minimum, 3 technically acceptable measurements 
were required, and if needed the measurements were repeated up to 8 times. The measured 
indices were forced vital capacity (FVC) and forced expiratory volume in one second (FEV1). 
FVC and FEV1 were presented as percentages of the means of age- and sex-specific, height-
related reference values (FVC% and FEV1%) (Viljanen et al. 1982). FEV1/FVC was counted 
based on FVC and FEV1 results and is presented as age- and sex-specific, height-related (% of 
predicted) values (FEV1/FVC%). In addition to baseline FVS measurement (pre-BD values), FVS 
was also performed 15 minutes after inhalation of 400µg salbutamol (Ventoline Evohaler 
0.1mg/dos, GlaxoSmithKline) (post-BD values) (Miller et al. 2005).  
 Irreversible airway obstruction was defined  in categorized analysis as post-BD 
FEV1/FVC% below 88% of the predicted value (FEV1/FVC%<88%) according to the Finnish age- 
and sex-specific, height-related cut-off limit that was settled at the level of -2 standard 
deviations (SD) (Z-score -1.96) in Finnish  non-selected adults (Viljanen et al. 1982) Since Finnish 
references are old and newer updated national references were not available, we also defined 
the irreversible airway obstruction by using the recently published, multi-ethnic, age-, sex- and 
height-adjusted Global Lung Function Initiative 2012 (GLI 2012) limits for abnormal FEV1/FVC 
–ratio (Quanjer et al. 2012). On the basis of this criterion, irreversible obstruction was 
considered to be present if post-BD FEV1/FVC-ratio was below 5th percentile (lower limit of 
normality), corresponding z-score -1.64 (FEV1/FVC<5th percentile).  
 
4.4.8 Skin prick testing and the definitions of atopy 
SPTs were performed on the forearms of 206 study subjects. ALK Soluprick® extracts were used 
(ALK, Copenhagen, Denmark), including the following allergens: birch, common alder, timothy 
grass, mugwort, dog, cat, horse, cow, dust mites (D. pteronyssinus, D. farinae, and Acarus siro), 
and one mold (C. herbarum). A weal with a diameter of at least 3 mm and half of the width of 
the positive control (histamine dihydrochloride) was considered as positive (The European 
Academy of Allergology and Clinical Immunology 1993, Bousquet et al. 2012).  
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Atopy was defined as the presence of at least one positive reaction for tested allergens. Allergic 
rhinitis and conjunctivitis were defined if there were seasonal symptoms or 
symptoms triggered by animal contacts during the preceding 12 months. Atopic eczema was 
defined as itchy eczema at typical locations requiring treatment during the preceding 12 
months. Clinical atopy was defined by the presence of allergic rhinitis, allergic conjunctivitis, or 
atopic eczema combined with atopic sensitization (one or more positive SPT results).  
 
4.4.9 Home Peak Expiratory Flow Monitoring 
PEF was measured using a Mini Wright PEF meter (Clement-Clarke International LTD, Harlow, 
Essex UK) three times every morning and every evening for two weeks. The best of the 3 values 
was included in the analyses if the difference between the two best values was less than 
40L/min (Miller et al. 2005). Daily diurnal variability over 20% between the PEF morning and 
evening values was considered abnormal (Asthma: Current Care Guidelines 2012, Quanjer et al. 
1997) if present at least twice during the follow-up. Daily diurnal PEF variability was calculated 
from twice daily PEF as [(day´s highest – day´s lowest) / mean of day´s highest and day´s 
lowest] x 100 (Global Initiative for Asthma 2014). During the second week, PEF was 
measured before and 15 min after the administration of inhaled bronchodilator in the morning 
(Salbutamol 0,4mg, Buventol easyhaler 0.1mg/dos, Orion Pharma, Finland) (Miller et al. 2005). 
PEF improvement of 15% or more (Asthma: Current Care Guidelines 2012), at least twice after 
the bronchodilator inhalation, was considered significant. PEF monitoring was considered 
appropriately completed if at least 7 acceptable morning and evening measurements and 3 days 
with acceptable pre- and post-treatment measurements were available. Of the 208 study 
subjects, 180 (87%) returned the PEF monitoring results, and 175 (84%) were considered as 
appropriately completed.  
 
4.4.10 Definition on Asthma 
Bronchial asthma was defined by two different ways to reflect the certainty of the diagnosis: 
doctor-diagnosed asthma and self-reported asthma.  
 For doctor-diagnosed asthma, an on-going regular maintenance medication with 
ICSs and a previously settled asthma diagnosis were required. In addition, study subjects who 
reported asthma-presumptive symptoms and/or repeated use of on-demand bronchodilators 
during the preceding 12 months and in addition had a pathological result in the home PEF 
monitoring were regarded to have doctor-diagnosed asthma.  Repeated wheezing episodes, 
chronic night cough, and prolonged cough for more than 4 weeks apart from infection were 
regarded as asthma-presumptive symptoms.  
 For self-reported asthma, previously diagnosed asthma combined with asthma-
presumptive symptoms or with repeated use of on-demand bronchodilators during the 
preceding 12 months was required. Cases with doctor-diagnosed asthma were included.  
4.5 STATISTICAL ANALYSES 
The data was analyzed using SPSS 19.0 - 21.0 software (SPSS Inc., Chicago, IL, USA). Chi-square 
and Fisher’s exact tests were used in the analyses of the categorized data. The Mann-Whitney 
U-test was used in the analysis of the continuous SGRQ scores, pack-years data and blood 
eosinophil counts. These results are presented with medians, 25-75 interquartile ranges (IQR), 
and ranges. Logistic regression was used in the multivariate analyses of categorized data, and 
the results are presented as adjusted p-values or adjusted odds ratios (OR) and their 95% 
confidence intervals (95%CI). Analysis of variance (ANOVA) adjusted for asthma and current 
daily smoking was used in the analysis of continuous lung function testing data. 
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4.6 ETHICS 
Consent for the original study plan was obtained from The Ethics Committee of Kuopio 
University Hospital on 26th May 1981. Parents were informed of the study and the voluntary 
nature of participation, but written consent for the participation of the child was not obtained. 
At the time of the study, blood tests and radiography were routine examinations in suspected 
cases of severe bronchiolitis or pneumonia. However, these examinations may have been 
omitted for some patients if they had not been participating in the study. Therefore, some of the 
patients in the study were exposed to blood tests and radiography as a result of their 
participation in the study, and all patients were exposed to increased follow-up visits. 
However, this was considered to be outweighed by the special attention paid to the diagnostics 
and follow-up of patients with hospitalized LRTI. 
The Ethics Committee of Pohjois-Savo Health-Care District approved the 30-year 
follow-up study (Permission number 76/2009, dated 20th January 2010). Informed written 
consent was obtained from all individual participants included in the follow-up study. 
Participation was voluntary and study subjects were able to discontinue the study at any phase. 
Clinical evaluation included interviews with the doctor, physical examination, FeNO 
measurement, lung function test with bronchodilatation, SPTs and two-week PEF monitoring. 
All study subjects were questioned about previous adverse reactions to STPs and 
bronchodilatation tests. If any reactions were suspected, the examinations were not performed. 
All measurements were considered fairly harmless to adult study subjects when compared to 
the valuable information gained about the long-term effects of early childhood LRTIs. We 
provided all participants with individual results and gave personal medical advice and directed 
participants to contact their own doctors for further advice in cases that resulted in new asthma 
diagnosis or imbalanced asthma. 
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5 Results 
5.1 ASTHMA IN ADULTHOOD AFTER EARLY CHILDHOOD BRONCHIOLITIS 
OR PNEUMONIA 
5.1.1 Characteristics of study groups 
There were 12 former bronchiolitis patients, 2 pneumonia patients and 28 control patients who 
returned the written questionnaires but did not attend the clinical study. There were no 
significant differences between those who did or did not attend the clinical study in 
presumptive asthma symptoms during the 12 month period, or prevalence of previously 
diagnosed (based on questionnaire only). In addition, there was no significant difference in the 
usage of continuous ICSs or on-demand bronchodilating drugs between those who did or did 
not attend the clinical study (data not shown). Those who did not attend the clinical study were 
excluded from the further analysis. 
There were no significant differences in sex distribution between the three study 
groups (Table 4). Fourteen (29%) former bronchiolitis patients, 10 (46%) former pneumonia 
patients, and 17 (12%) control subjects were current daily smokers. The amount of smoked 
pack-years was also significantly higher in the bronchiolitis group compared to controls. There 
were no significant differences between study groups in prevalence of asthma presumptive 
symptoms, such as chronic night cough, prolonged cough, or repeated wheezing. However, the 
use of on-demand bronchodilators and regular ICSs were more common in former bronchiolitis 
patients than in controls (Table 4).   
 
5.1.2 Asthma and Atopy 
Allergic symptoms and atopic sensitization were common in all study groups. Atopic 
sensitization was found in 30 (64%) study subjects in the bronchiolitis group (p = 0.558 vs. 
controls), 12 (55%) in the pneumonia group (p = 0.690 vs. controls), and 79/136 (58%) in controls. 
In addition, 23 (48%) former bronchiolitis patients (p = 0.724 vs. controls), 10 (46%) former 
pneumonia patients (p = 0.674 vs. controls), and 66/136 (49%) controls were diagnosed to have 
clinical atopy, e.g., positive reaction in SPT´s combined with allergic symptoms. 
 Doctor-diagnosed asthma was present altogether in 32/208 study subjects. Of these 
subjects 27 (84%) had previously diagnosed asthma at some time of life, and 22 had previously 
diagnosed asthma in addition to having used continuous ICSs during the previous 12 months. 
Ten study subjects were diagnosed to have doctor-diagnosed asthma due to asthma-
presumptive symptoms and/or repeated use of inhaled bronchodilating drugs and pathology in 
PEF follow-up. Five of these had previously diagnosed asthma, so only 5 completely new 
asthma diagnoses were made in the whole study population, 1 in pneumonia group and 4 in 
control group. All former bronchiolitis patients who had doctor-diagnosed asthma also had 
previously diagnosed asthma at some time of life.  Self-reported asthma was present in an 
additional 10 cases. Both doctor-diagnosed asthma and self-reported asthma were significantly 
more common in former bronchiolitis patients compared to controls (Figure 2). Asthma figures 
by both definitions were similar in the former pneumonia patients and in controls (Figure 2).  
 Doctor-diagnosed asthma was present in 10/43 (23%) former RSV LRTI patients and 
11/86 (13%) controls (p=0.188; adjusted for age, sex, clinical atopy, and current daily smoking).  
In addition, self-reported astma was present in 28% of the former RSV LRTI patients compared 
to 17% in control group (adjusted p-value= 0.248). In line with these results, the FENO values 
were almost equal in both groups; the mean (95%CI) was 20 (13-27) in the RSV LRTI group and 
20 (17-23) in controls (p=0.948). However, in subgroup analyses 9/27 (33%) former wheezing 
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RSV bronchiolitis patients had doctor-diagnosed asthma, which was significantly more 
compared to controls (p=0.038 vs. controls). There was no significant difference between RSV 
pneumonia patients (6%) and controls in the prevalence of asthma (p=0.160 vs. controls).  
 
Table 4. Basic characteristics and the prevalence of asthma presumptive symptoms in the three 
study groups. 
 
 
Bronchiolitis 
N=48 p-value
1 Pneumonia 
N=22 p-value
1 Control 
N=138 
Sex (male) 30 (63%) 0.326 8 (36%) 0.117 75 (54%) 
Age 29.5 (0.72) 0.420 29.4 (0.58) 0.163 29.6 (0.75) 
Current daily smoking 14 (29%) 0.007 10 (46%) <0.001 17 (12%) 
Smoked pack-years, 
median (range)2 0.1 (0.0-25.0) 0.036 0.5 (0.0-22.5) 0.064 0.0 (0.0-25.0) 
Asthma symptoms      
Chronic night cough3 5 (10%) 0.311 5 (23%) 0.191 6 (4%) 
Prolonged cough3 5 (10%) 0.861 5 (23%) 0.152 12 (9%) 
Repeated wheezing3 16 (33%) 0.487 7 (32%) 0.898 37 (27%) 
Use of asthma medication      
Bronchodilating drugs3 17 (35%) 0.002 2 (9%) 0.546 20 (15%) 
Inhaled cortcosteroids3 10 (21 %) 0.023 1 (5%) 0.539 12 (9%) 
1 Paired comparisons vs. population controls  
2 Pneumonia group N=20, Control group N=135 
3 P-values are presented adjusted for age, sex, clinical atopy and current daily smoking 
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Figure 2. Asthma by two definitions at the age period of 28-31 years in the study subjects 
hospitalized for bronchiolitis or pneumonia at less than 24 months of age compared with population 
controls. 1paired comparison between bronchiolitis and control group and 2paired comparison 
between pneumonia and control group as adjusted for age, sex, clinical atopy, and current daily 
smoking. 
 
5.2 LUNG FUNCTION IN ADULTHOOD AFTER EARLY CHILDHOOD LRTI 
Pre-BD and post-BD FVC%, FEV1%, and FEV1/FVC% were lower in former bronchiolitis 
patients than in controls (Figure 3). Instead, the former pneumonia patients had lower pre-BD 
and post-BD FEV1% compared to controls (Figure 3). There were no significant differences 
between the bronchiolitis and pneumonia groups (Figure 3). Mean FEV1% response to 
bronchodilator was 4.3% (95%CI 3.5-5.2%) in bronchiolitis group, 4.3% (2.2-6.3%) in pneumonia 
group and 4.3% (3.5 – 5.2%) in control group with no significant differences between groups. 
Post-BD FEV1/FVC% was below 88% of predicted in 10 (21%) former bronchiolitis 
patients, 2 (9%) former pneumonia patients, and 5 (4%) controls. The respective figures for 
FEV1/FVC<5th percentile, according to the GLI 2012 references, were 7(15%), 1(5%), and 2(1%). 
The study groups (bronchiolitis, pneumonia, control), asthma and current smoking were 
included as covariates in the logistic regression. Belonging to the bronchiolitis group was an 
independently significant risk factor for irreversible airway obstruction by the Finnish 
references and belonging to the bronchiolitis group and the presence of current asthma by the 
GLI 2012 references (Table 5).  
There were no significant differences in pre-BD or post-BD FVC% values between 
the RSV LRTI and control group (Figure 4). However, both pre-BD and post-BD FEV1% and 
FEV1/FVC% were significantly lower in the former RSV LRTI patients compared to controls 
(Figure 4). The lung function disorders were of the obstructive type, i.e., not responding to 
bronchodilators, which confirms the presence irreversible airway obstruction after early 
childhood RSV LRTI. 
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Figure 3. Pre- and post-bronchodilator lung function at the age period of 28-31 years after 
bronchiolitis or pneumonia in infancy compared to controls presented as means and 95% confidence 
intervals (95%CI). Analysis of variance and statistically significant differences between study groups 
are presented in the figure. P-values are adjusted with asthma and current daily smoking, * p < 
0.05, ** p < 0.005, *** p < 0.001. 1Pre-BD, pre-bronchodilator; post-BD, post-bronchodilator, 
2FVC%, forced vital capacity (% of predicted value, 3FEV1%, forced expiratory volume in one second 
(% of predicted value, 4FEV1/FVC%, FEV1/FVC ratio presented as % of predicted value  
 
Table 5. Hospitalization for bronchiolitis or pneumonia in infancy, current asthma, and current daily 
smoking at 28-31 years of age as risk factors for irreversible airway obstruction. 
Risk factors for 
irreversible airway 
obstruction 
FEV1/FVC% < 
88%1 
N = 17 
Adjusted OR2 
(95%CI) 
FEV1/FVC<5th 
percentile3 
N = 10 
Adjusted OR2 
(95%CI) 
Bronchiolitis group 10/47 (21%) 5.6 (1.7 – 18.2) 7/47 (15%) 7.1 (1.3 – 37.2) 
Pneumonia group 2/22 (9%) 2.2 (0.3 – 13.6) 1/22 (5%) 1.7 (0.1 – 24.8) 
Current daily smoking 15/41 (12%) 1.2 (0.4 – 4.0) 4/41 (10%) 2.2 (0.5 – 10.1) 
Asthma 8/42 (19%) 2.8 (1.0 – 8.3) 7/42 (17%) 7.6 (1.8 – 32.6) 
1Post-bronchodilator FEV1/FVC-ratio below 88% of predicted value 
2All variables (group, current daily smoking and asthma) are included in the same logistic regression 
model 
3FEV1/FVC-ratio below 5th percentile lower limit of normality (GLI 2013 references) 
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Figure 4. Pre- and post-bronchodilator lung function in adulthood after RSV lower respiratory tract 
infection (RSV LRTI) in infancy compared to controls presented as means and 95% confidence 
intervals (95%CI). Analysis of variance and statistically significant differences between study groups 
are presented in the figure. P-values are adjusted with age, sex, current daily smoking, and atopy, 
*** p < 0.001. 1Pre-BD, pre-bronchodilator; post-BD, post-bronchodilator, 2FVC%, forced vital 
capacity (% of predicted value, 3FEV1%, forced expiratory volume in one second (% of predicted 
value, 4FEV1/FVC%, FEV1/FVC ratio presented as % of predicted value.  
5.3 THE SIGNIFICANCE OF EARLY RISK AND PROTECTIVE FACTORS FOR 
ASTHMA AND LUNG FUNCTION IMPAIRMENT IN ADULTHOOD 
Previously described early risk factors for later asthma (e.g., parental asthma, parental atopy, 
atopy at the age of less than 2 years, and non-RSV ethiology of bronchiolitis) had lost their 
significance at the age period of 28-31 years (Table 6). Repeated wheezing at the age of less than 
2 years was a significant factor for asthma in adulthood (Table 6). However, this association was 
not independent of parental asthma, since all former bronchiolitis patients who had history of 
parental asthma experienced repeated wheezing by the age of 2 years. So, repeated wheezing 
under 2-years of age lost its significance as an independent asthma risk factor in multivariate 
analysis, including parental asthma, current smoking, early childhood atopy, and gender (OR, 
95%CI 5.5, 0.8-37.1). None of these assumed risk factors had an association with FVC%, FEV1%, 
or FEV1/FVC% in adulthood when lung function was analysed as continuous variables. Results 
for FEV1/FVC% are presented in Figure 5. When lung function was analysed as categorized 
variables,  those with the history of parental asthma had Post-BD FEV1/FVC<5th percentile  
significantly more often compared to those with no such history (OR, 95%CI 16.52, 1.09-249.88 
in multivariate analysis with gender, current smoking, atopy, and repeated wheezing at under 
2-years-of-age included).  
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Table 6. Prevalence of early life factors in 47 former bronchiolitis patients, with and without asthma, 
at the age period of 28-31 years. 
 
 
Self-reported 
asthma1 N (%) 
No asthma N (%) OR (95%CI)2 
Early childhood factor    
Parental asthma3 N=7/44 3/14 (21%) 4/30 (13%) 1.8 (0.3 – 9.4) 
Parental atopy4 N=14/44 3/14 (21%) 11/30 (34%) 0.5 (0.1 – 2.1) 
Repeated wheezing5 N=31/45 15/17 (88%) 16/28 (57%) 6.2 (1.2 – 33.1) 
Atopy6 N=24/45 10/17 (59%) 14/28 (50%) 1.3 (0.4 – 4.7) 
Non-RSV bronchiolitis N=33/47 11/17 (65%) 22/30 (73%) 0.7 (0.2 – 2.6) 
1For definition of asthma, see the text 
2Odd´s ratio and 95% confidence interval, adjusted for current daily smoking 
3Doctor-diagnosed parental asthma present 
4Doctor-diagnosed parental atopic dermatitis and/or hay fever present 
5More than 2 doctor-diagnosed wheezing episodes before the age of 2 years 
6Doctor-diagnosed atopic eczema and/or high serum IgE >60 IU//L at the age of less than 2 years 
 
 
 
Figure 5. Pre- and post-bronchodilator FEV1/FVC% in adulthood in relation to early childhood risk 
factors presented as means and 95% confidence intervals (95%CI). Analysis of variance showed 
that no statistically significant differences were found, and p-values are not presented in the figure. 
P-values are adjusted with age, sex, current daily smoking. 1Pre-BD, pre-bronchodilator; post-BD, 
post-bronchodilator, 2Doctor-diagnosed parental asthma present, 3Doctor-diagnosed parental atopic 
dermatitis and/or hay fever present, 4More than 2 doctor-diagnosed wheezing episodes before the 
age of 2 years, 5Doctor-diagnosed atopic eczema and/or high serum IgE >60 IU//L at the age of less 
than 2 years, 6Bronchiolitis cause by other viruses than RSV 
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The median of eosinophils on admission among 47 study subjects included in the analysis was 
0.11 x10E9/l (IQR 0.03 – 0.41); on convalescence the respective value was 0.24 x10E9/l (0.12 – 
0.38). Study subjests with self-reported asthma in adulthood had significantly higher eosinophil 
counts on admission to hospital compared to those who did not have adulthood asthma (Figure 
6). There were no significant differences between eosinophil counts on convalescence in early 
childhood between the study subjects with or without asthma in adulthood (Figure 6). We 
continued the analysis with categorizing eosinophil counts into high (>0.45x10E9/l) or low 
(<0.25x10E9/l) on admission or on convalescence. Study subjects with high eosinophil count on 
convalescence outside the infection had increased risk for asthma compared to those with 
normal or low eosinophil count on convalescence (Table 7), whereas low eosinophil count 
during bronchiolitis decreased the risk of asthma in adulthood (Table 7).  
There were no significant differences between eosinophils on admission or 
eosinophils on convalescence and FEV1/FVC-ratio below 5th percentile in adulthood. However, 
high eosinophil count outside the infection was a significant risk factor for irreversible airway 
obstruction (FEV1/FVC-ratio below 5th percentile) in adulthood (OR 8.35, 95%CI 1.15 – 60.64). 
Analyses were adjusted with gender, current smoking and atopy in infancy, and all these 
associations were independent from atopic status in infancy.  
 
 
 
 
Figure 6. Blood eosinophils (median, interquartile range, range) on admission to hospital for 
bronchiolitis before the age of 2 years and on convalescence 4-6 weeks later in relation to self-
reported asthma in adulthood. 1Blood eosinophils on admission to hospital for bronchiolitis, 2Blood 
eosinophils on convalescence 4-6 weeks after bronchiolitis.  
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Figure 7. Blood eosinophils (median, interquartile range, range) on admission to hospital for 
bronchiolitis before the age of 2 years and on convalescence 4-6 weeks later in relation to 
FEV1/FVC-ratio below 5th percentile in adulthood. 1Blood eosinophils on admission to hospital for 
bronchiolitis, 2Blood eosinophils on convalescence 4-6 weeks after bronchiolitis, 3FEV1/FVC below or 
above the 5th percentile of lower limit of normality. 
 
 
Table 7. Blood eosinophils on admission to hospital for bronchiolitis and on convalescence in relation 
to self-reported asthma in adulthood in 47 former bronchiolitis patients. 
 
 
Self-reported 
asthma1 N = 17 
No asthma N = 30 OR (95%CI)2 
Blood eosinophils  <0.25x10/E9/l 
on admission3 (N=28) 
6 (35%) 22 (73%) 0.17 (0.04 – 0.68) 
Blood eosinophils >0.45x109/l on 
admission3 (N=11) 
5 (29%) 6 (20%) 2.00 (0.44 – 9.14) 
Blood eosinophils <0.25x109/l on 
convalescence4 (N=25) 
7 (41%) 18 (60%) 0.40 (0.11 – 1.47) 
Blood eosinophils  >0.45x10/E9/l 
on convalescence4 (N=9) 
7 (41%) 3 (10%) 6.30 (1.13 – 35.30) 
1For definition of asthma, see the text, 2Odds ratio, logistic regression: adjusted with gender, 
current smoking and atopy in infancy and 95% confidence interval, 3On admission to hospital for 
bronchiolitis, 4On convalescence, 4-6 weeks after bronchiolitis 
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5.4 HEALTH-RELATED QUALITY OF LIFE AFTER EARLY CHILDHOOD LRTI 
Both former bronchiolitis patients and former pneumonia patients had significantly higher total 
scores in the SGRQ than controls (Table 8).  The former bronchiolitis group differed from the 
control group in all parts of the questionnaire, whereas the former pneumonia group differed in 
terms of symptom scores (Table 8). The study subjects were divided into two groups on the 
basis of SGRQ scores (lower vs. higher than the median of the controls). In the bronchiolitis 
group, 73% of study subjects (OR, 95%CI 2.6, 1.5 – 5.6 vs. controls) had SGRQ total scores above 
the median of the controls, as adjusted with age, sex, current smoking and clinical atopy; in the 
pneumonia group, this value was 77% of study subjects (3.7, 1.2 – 11.2 vs. controls),  indicating 
that these differences were independent from smoking.  
After RSV LRTI in early childhood, the median total scores in SGRQ were 3.4 (IQ 
25-75 1.1 – 15.2) in RSV LRTI and 1.5 (0.0 – 5.4) in control group (p=0.007), reflecting the lower 
respiratory health-related quality of life in adulthood after RSV LRTI in infancy.  
 
 
Table 8. The scores calculated from the St. George’s Respiratory Questionnaire in the three study 
groups 
 
 
Bronchiolitis N=48 Pneumonia N=22 Control N=138 
SGRQ 
components 
Median 
IQR1 25 - 75 
p – value2 
Median 
IQR1 25 - 75 
p – value2 
Median 
IQR1 25 - 75 
Symptom score 9.1 
0.0 – 26.3 
0.044 
18.4 
5.1 – 29.9 
0.005 
5.0 
0.0 – 16.3 
Activity Score  5.7 
0.0 – 12.1 
0.002 
0.0 
0.0 – 13.4 
0.146 
0.0 
0.0 – 6.0 
Impact Score 2.4 
0.0 – 9.5 
< 0.001 
0.0 
0.0 – 8.4 
0.475 
0.0 
0.0 – 2.4 
Total Score 5.4 
0.0 – 14.7 
< 0.001 
4.9 
1.3 – 14.8 
0.012 
1.5 
0.0 – 6.0 
1 Interquartile range 
2 Paired comparisons vs. controls; non-adjusted p-values 
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6 Discussion 
6.1 STUDY DESIGN AND SUBJECTS 
6.1.1 Study design 
This study is a prospective follow-up of a cohort of children who were recruited in 1981-82 at 
the hospitalization for bronchiolitis or pneumonia under 24 months of age. This cohort has been 
followed-up for almost 30 years, and at the time of the present follow-up, the study subjects 
were adults between 28-31 years old. After the collection of early childhood data before the age 
of 3 years, 3 clinical follow-up studies have been carried out at the age periods of 4.5-6 years 
(Kuikka et al. 1994), 8.5-10 years (Korppi et al. 1994), and 18-20 years (Piippo-Savolainen et al. 
2004). In addition, 2 postal questionnaire studies were carried out at the age periods of 13.5-16 
years (Hyvarinen et al. 2005) and 26-29 years (Ruotsalainen et al. 2010a). 
Previously, this cohort has provided information about the viral etiology and long-
term outcome of of early childhood LRTIs (Piippo-Savolainen et al. 2004, Kuikka et al. 1994, 
Korppi et al. 1994, Hyvarinen et al. 2005, Korppi et al. 1986, Ruotsalainen et al. 2010a). The long-
term outcome has been studied in relation to asthma, atopy, and lung function (Piippo-
Savolainen et al. 2004, Kuikka et al. 1994, Korppi et al. 1994, Hyvarinen et al. 2005, Korppi et al. 
1986, Ruotsalainen et al. 2010a). It has also provided information about the long-term outcome 
of LRTIs in relation to etiology of initial LRTI (Korppi et al. 2004, Piippo-Savolainen et al. 2007, 
Ruotsalainen et al. 2010b). 
 The present 30-year follow-up was perfomed to answer questions regarding the 
adulthood outcome of children who presented LRTI in early childhood (in terms of asthma 
prevalence, lung function, and HRQoL) as well as to determine the effect of RSV etiology of 
LRTI on these outcomes. This is the longest active post-LRTI cohort in the world, and it is 
uniquely positioned to answer the questions about the adulthood outcome of early childhood 
LRTIs in a prospective setting.  
 In practice, the present follow-up was performed as a moving clinic, and the study 
subjects were examined in their present home cities. All the equipment for study examinations 
were the same for all study subjects, and spirometry and FeNO were calibrated and performed 
as recommended by the international guidelines. All examinations were performed by two 
research doctors and one respiratory nurse, which reduces the variability of the findings. 
 
6.1.2 Study subjects 
Originally, 83 bronchiolitis and 44 pneumonia patients were recruited in the study. The study 
subjects represent a selected population of hospitalized LRTI patients, as it is known that about 
30-40% of children develop bronchiolitis before the 2 years of age (Zorc & Hall 2010, Ralston et 
al. 2014), but only 1-3% are hospitalized for it (Nagakumar & Doull 2012, Smyth & Openshaw 
2006, Henderson et al. 2005). The original bronchiolitis cohort represented 1-1.5% of the 
population under two years of age in the area and is therefore a representative and non-selected 
sample of hospitalized LRTI patients (Piippo-Savolainen 2006). Since non-wheezing pneumonia 
patients were also included in the study, the comparison between non-wheezing and wheezing 
LRTI patients was possible, adding to the uniqueness of this study. 
The study design did not include controls from the beginning of the study. 
However, pneumonia patients were used as non-wheezing controls throughout childhood. 
Selected controls from a prospective atopy prevention study were used at the 8-10, 18-20 and 
26-29 year follow-ups (Piippo-Savolainen et al. 2004, Korppi et al. 1994, Ruotsalainen et al. 
2010a), and population based controls were used at the 26-29 year follow-up (Ruotsalainen et al. 
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2010a) and at the present 30-year follow-up. In 2010, at the age period of 28-31 years, 48(58%) 
bronchiolitis patients, 22(50%) pneumonia patients, and 166(34%) controls attended the clinical 
study. The attendance rate of the original study group was rather low, which is understandable, 
since the cohort has been followed-up for almost 30 years. There were no differences in gender 
or age distribution between the study groups. 
6.2 ASTHMA AFTER EARLY CHILDHOOD BRONCHIOLITIS OR PNEUMONIA 
 
6.2.1 Definitions of bronchiolitis and pneumonia 
During the recruitment of study subjects less than 24 months of age in 1981-82, the definition of 
bronchiolitis included a prolonged expiratory phase and expiratory wheezing. Pneumonia 
patients were diagnosed based on symptoms of viral LRTI without wheezing but an interstitial 
infiltration on chest radiograph was required (Korppi et al. 1986). The definition of bronchiolitis 
age limit and symptoms varies in different countries. In the enrollment of patients, the age limit 
of 24 months was used for bronchiolitis as in other studies in the eighties (Wennergren et al. 
1992). This age limit is still in use in several current guidelines (Ralston et al. 2014, Scottish 
Intercollegiate Guideline Network 2012). Wheezing in children under three years of age can be 
classified as two different clinical conditions, wheezing bronchitis and bronchiolitis (Tapiainen 
et al. 2015). To reduce the heterogeneity of clinical definitions, several studies and guidelines 
recently suggested an age limit of 12 months for bronchiolitis (Zorc & Hall 2010, Tapiainen et al. 
2015, Mecklin et al. 2014, Smyth & Openshaw 2006, Henderson et al. 2005); wheezing from 12 
months onward is called wheezing bronchitis (Tapiainen et al. 2015). However, bronchiolitis 
and wheezing bronchitis still have a significant overlap, and it has been suggested that the term 
bronchiolitis for the initial wheezing episode is irrelevant due to inaccurate, symptom-based 
classification (Brand et al. 2008). As has been done in previous study follow-ups, using the term 
“bronchiolitis” in these wheezing children is accurate enough and adheres to currently used 
guidelines supporting this definition (Ralston et al. 2014, Scottish Intercollegiate Guideline 
Network 2012). 
There is also significant heterogenity in the definition of acute bronchiolitis 
symptoms. Some definitions emphaze audible wheezing, while in other definitions, wheezing is 
not required for the diagnosis (Elphick et al. 2007, Everard 2006). It can be argued whether or 
not our definition of pneumonia, especially in case of RSV pneumonia, is part of the same entity 
as bronchiolitis. However, it has been demonstrated that wheezing during LRTI may be a 
significant symptom when evaluating the later outcome of LRTI (Elphick et al. 2007). Our 
classification, also used in previous follow-ups of the cohort, has enabled us to differentiate the 
outcome of LRTI in terms of wheezing and non-wheezing LRTI.  
 
6.2.2 Definition of asthma 
The definition of asthma was based on the previous follow-ups of the cohort with only minor 
modifications (Piippo-Savolainen et al. 2004, Ruotsalainen et al. 2010a). Doctor-diagnosed 
asthma was based on regular use of ICSs and a previously settled asthma diagnosis or a 
pathological result in the home PEF monitoring combined with symptoms; so, the definition 
was rather strict.  
 It has been suggested that asthma may be a continuum and that choosing a cut-off 
point for a dichotomous asthma definition may unnecessarily reduce power of the study 
(Pekkanen et al. 2005). To avoid underdiagnosis of asthma, another definition based on less 
strict self-reported asthma was used as in previous follow-ups of the cohort (Piippo-Savolainen 
et al. 2004, Ruotsalainen et al. 2010a). Previous doctor-diagnosed asthma combined with 
asthma-presumptive symptoms or with repeated use of on-demand bronchodilators during the 
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preceding 12 months was required for the diagnosis of self-reported asthma. So this definition 
was very close to the definition of doctor-diagnosed asthma and was considered reliable to 
describe asthma prevalence in our study population. To avoid type 2 error in statistical analysis 
this definition was used in the analysis of early childhood risk factors.  Only 5 new cases of 
doctor-diagnosed asthma were made in whole study population; they form 16% of all asthma 
cases. All others had previously diagnosed asthma at some time of their lives. This means that 
the definitions of asthma fits with real asthma morbidity in our study population rather well. 
 
 6.2.3 Prevalence of asthma 
Asthma prevalence at the age period of 28-31 years was 31-35% in the bronchiolitis group, 9-
23% in the pneumonia group, and 11-15% in the control group, depending on definiton. 
Bronchiolitis patients had asthma significantly more often compared to controls, but other 
differences were not significant.  However there were no significant differences between the 
three study groups in asthma presumptive symtoms. This may reflect the proportion of treated 
asthma among former bronhiolitis patients, since inhaled conticosteroids were significantly 
more often used in the bronchiolitis group compared to controls. 
 In previous studies, the prevalence of asthma has been 5-9% in the Finnish adult 
population (Huurre et al. 2004, Pallasaho et al. 2011, Laatikainen et al. 2011). Compared to these 
figures, a 31-35% prevalence of asthma after bronchiolitis in early childhood seems high. 
Moreover, the asthma prevalence in the controls was 10-15%, which is slightly higher than the 
5-9% asthma prevalence in the Finnish adult population in general. This probably demonstrates 
that symptomatic controls are more likely to attend studies than non-symptomatic ones. There 
is only one comparable prospective post-bronchiolitis study from Sweden that has continued to 
adulthood (Goksor et al. 2015). In line with our results, the 37% asthma prevalence after 
hospitalization for bronchiolitis was found in the latest follow-up of this cohort at the age 
period of 25-28 years (Goksor et al. 2015). In addition, at the age period of 17-35 years, the 38% 
asthma prevalence was established in hospitalized patients in a retrospective post-bronchiolitis 
study (Larouch et al. 2000). 
 Although the prognosis of early childhood wheezing is favorable in the majority of 
children, it has been established that wheezing illness in childhood is associated with an 
increased risk for persistent asthma or relapse in early adulthood (Stern et al. 2008, Sears et al. 
2003). In the case of asthma remission, symptoms usually disappear during puberty and 
reappear in early adulthood (Stern et al. 2008, Sears et al. 2003, Butland & Strachan 2007). It has 
been demonstrated asthma relapse at the age of 22-26 years can be predicted by bronchial 
hyperreactivity (Stern et al. 2008, Rasmussen et al. 2002) and low airway function (Stern et al. 
2008) at the age of 6 years, as well as late-onset or persistent wheezing (Stern et al. 2008), 
childhood atopy (Sears et al. 2003) and a younger age at onset of wheezing (Sears et al. 2003). 
This phenomenon of asthma remission and relapse after early childhood wheezing has also 
been described in the present cohort (Piippo-Savolainen & Korppi 2008). In the present cohort, 
25% of children reported asthma at ages 4–6 years after bronchiolitis, as compared with only 14-
15% at ages 8–15 (Korppi et al. 1993, Kuikka et al. 1994, Korppi et al. 1994, Hyvarinen et al. 
2005). However, the prevalence of doctor-diagnosed asthma rose to 30-41% in early adulthood 
(ages 18–20 years) (Piippo-Savolainen et al. 2004). After the increase in asthma prevalence in 
early adulthood no further increase in asthma prevalence had happened at the age of 28-31 
years. In the previous follow-up, between 26-29 years of age, asthma prevalence after 
bronchiolitis was 20-41%, but the diagnosis of doctor-diagnosed asthma was based on posted 
questionnaire only; therefore, the figures may not be totally comparable between these follow-
ups (Ruotsalainen et al. 2010a).  
 In the present study, asthma risk after pneumonia in early childhood was not 
increased compared to controls, which is in line with the previous follow-up of the cohort 
(Piippo-Savolainen et al. 2004). The 20-year clinical follow-up of this cohort demonstrated 15-
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21% asthma prevalence in former pneumonia patients (Piippo-Savolainen et al. 2004) and the 
asthma prevalence of 9-23% in the present follow-up was comparable to these figures. 
However, in the recent follow-up of the Tucson birth cohort increased asthma risk was 
demonstrated after early childhood pneumonia at the age of 26 years (Chan et al. 2015). It may 
be that in case of asthma prevalence after pneumonia in early childhood our study results 
should be interpreted with a caution because of small number of study subjects in the 
pneumonia group. 
 As a conclusion, asthma risk is increased at the age of 28-31 years after 
hospitalization for the early childhood bronchiolitis group compared to controls with no history 
of early childhood LRTI hospitalization. Asthma prevalence of 31-35% in adulthood after 
bronchiolitis is in line with previous study results and asthma prevalence remains quite stable 
between the ages of 20-30 years. Asthma risk after early childhood pneumonia was not 
increased compared to controls in the present follow-up, and these results are contradictory to 
those found in the recent 26-year follow-up of the Tucson cohort (Chan et al. 2015). Overall, 
studies about the asthma prevalence after early childhood pneumonia are scarce. 
6.3 LUNG FUNCTION IN ADULTHOOD AFTER EARLY CHILDHOOD LRTI 
6.3.1 Lung function impairment in adulthood after early childhood LRTI 
Previous studies that collected childhood data retrospectively demonstrated that lung function 
abnormalities and the prevalence of COPD are increased in adulthood after LRTIs in infancy 
(Lamprecht et al. 2011, Barker et al. 1991, Svanes et al. 2010).  In line with this, lung function 
impairment after early LRTI in childhood has been demonstrated in several prospectively 
followed-up cohorts in childhood (Sigurs et al. 2005, Kotaniemi-Syrjanen et al. 2008, Hyvarinen 
et al. 2007, Wennergren et al. 1997, Stein et al. 1999) and in adolescence or early adulthood 
(Piippo-Savolainen et al. 2004, Sigurs et al. 2010, Goksor et al. 2008, Korppi et al. 2004). Due to 
these previous findings, we hypothesized that signs of irreversible obstruction might be seen at 
the age of 30 years in our prospectively followed-up cohort. Irreversible obstruction is the 
typical lung function abnormality in COPD, and if found in adults with history of early 
childhood LRTI, it might suggest that early childhood LRTI patients are at inceased risk for 
COPD in later adulthood.  
In the present 30-year follow-up, the FVC%, FEV1%, and FEV1/FVC-ratio% were 
decreased in adulthood before and after bronchodilatation in former bronchiolitis patients, and 
FEV1% was reduced before and after bronchodilatation in pneumonia patients. However, there 
were no significant differences between the three study groups in response to bronchodilating 
drugs. These findings alone suggest irreversible type of bronchial obstruction after 
bronchiolitis. In pneumonia patients, these findings were not so obvious but of similar type.  
In categorized analysis, irreversible obstruction, defined as FEV1/FVC% <88% 
according to the Finnish reference values (Viljanen et al. 1982), was present in 21% of former 
bronchiolitis patients, in 9% of former pneumonia patients, and in 4% of controls. The 
respective figures for the FEV1/FVC<5th percentile, according to the GLI 2012 reference values 
(Quanjer et al. 2012), were 15%, 5%, and 1%, with significant differences between the 
bronchiolitis and control groups by both definitions. 
Our results are in line with the results of two Swedish post-bronchiolitis cohorts. 
Reduced FEV1/FVC-ratio before and after bronchodiatation was demonstrated in adults 17-20 
years old, indicating at least partial irreversibility of bronchial obstruction after early childhood 
bronchiolitis (Sigurs et al. 2010, Goksor et al. 2008). In the previous follow-up of our cohort, at 
the age of 18-20 years, the FEV1/FVC-ratio was also reduced, which is consistent with present 
results, but the bronchodilatation test was not performed during the follow-up (Piippo-
Savolainen et al. 2004). An obstructive type of lung function reduction has been recently 
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described to be present after early childhood pneumonia, which is in line with our findings 
(Chan et al. 2015). The obstructive type of lung function reduction after both bronchiolitis and 
pneumonia in early childhood may also suggest that these diseases share the same 
predisposition and may also share a similar type of outcome in adulthood with regards lung 
function.  
It has been proposed that FEV1/FVC<5th percentile should be used as a cut-off limit 
for COPD, because the GOLD cut-off criterion FEV1/FVC<0.7 underestimates the prevalence of 
COPD in young adults (Quanjer et al. 2012, Culver 2015). However, regardless of criterion used, 
the lung function data should always be assessed together with symptoms and prior probability 
of the COPD to diagnose the disease (Culver 2015). It was not our aim to assess the prevalence 
of COPD in our study population, and the diagnosis of COPD was not made. However, it is 
clear that signs of irreversible obstruction that is characteristic of COPD was found in our study 
subjects, since 15% of former bronchiolitis patients and 5% of pneumonia patients presented 
FEV1/FVC<5th percentile. The meaning of these findings in our study population remains 
unclear. However, in another study, modified FEV1/FVC<5th percentile was associated with an 
increased risk of death and prevalence of respiratory symptoms (Vaz Fragoso et al. 2010). 
As maximal lung function is reached in early adulthood, subjects who start their 
adult life with a lower FEV1/FVC-ratio may attain the threshold of COPD earlier, during 
normal lung ageing, than those starting with a higher FEV1/FVC-ratio (Martinez 2009).  The 
results of the 18-20 year follow-up and the present follow-up of our cohort demonstrate that 
subjects with the history of severe bronchiolitis in early childhood more often have obstructive 
airways in adolescence and adulthood compared to controls with no such history. At the 
present follow-up, when the cohort was studied at the age of 30 years, it became evident that 
these former LRTI patients never reach the full lung function capacity in early adulthood, and it 
is possible that these alterations progress to COPD during normal lung ageing in the future.  
6.4 PREDICTIVE FACTORS FOR ASTHMA AND LUNG FUNCTION IN 
ADULTHOOD 
6.4.1 Asthma and lung function in relation to viral etiology of LRTI 
It has been shown that RSV bronchiolitis is strongly associated with wheezing and asthma in 
childhood, but this relationship decreases with increasing age (Regnier & Huels 2013) and turns 
insignificant at school age (Stein et al. 1999). However, in a Swedish post-bronchiolitis study, 
increased risk for asthma was still seen at the age period of 15-18 years (Sigurs et al. 2010). 
Definitions of bronchiolitis and viral-induced wheezing are based on symptoms and have a 
significant overlap (Brand et al. 2008). Most likely, it does not matter if this LRTI is called 
bronchiolitis, wheezing bronchitis or viral-induced wheezing. Thus, differences in the definition 
of bronchiolitis between studies may explain part of the differences in the subsequent asthma 
risk. 
 Non-RSV etiology, especially rhinovirus etiology of bronchiolitis, has been 
associated with increased asthma risk even more distinctly compared to RSV etiology 
(Kotaniemi-Syrjanen et al. 2003, Reijonen et al. 2000, Piippo-Savolainen et al. 2007, Mikalsen et 
al. 2012, Beigelman & Bacharier 2013, Koponen et al. 2012). In the 18-20 year follow-up of the 
present cohort, 41-50% of former non-RSV bronchiolitis patients and 18-27% of RSV patients 
had asthma, and thus, non-RSV was a strong predictor for asthma in adulthood (Piippo-
Savolainen et al. 2007). However at the age period of 26-29 years, this difference could not be 
demonstrated (Ruotsalainen et al. 2010a).  
 In the present follow-up 43% of former RSV bronchiolitis patients and 33% of non-
RSV patients had self-reported asthma. Viral etiology of bronchiolitis had lost its significance 
since no significant difference was found between RSV or non-RSV bronchiolitis patients in 
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relation to asthma or lung function in adulthood. It may be that, like in case of RSV infection, 
the importance of non-RSV etiology of viral wheezing as a future asthma risk factor decreases 
with increasing age, probably due to several other environmental factors that are faced by the 
host in later life. However, there are no other studies to support this hypothesis. 
 In the present follow-up, former RSV LRTI patients were also compared with 
population controls, and there was no significant difference in asthma prevalence in adulthood. 
This finding is in line with the previous follow-up of this cohort, since at the age period of 18-20 
years, no significant associations were found between RSV LRTI and asthma (Korppi et al. 
2004). In addition, it was recently presented that non-hospitalized RSV LRTI plays no role as a 
risk factor for asthma at the age period of 26-29 years of age (Voraphani et al. 2014). 
 However, when only bronchiolitis patients who had wheezing during 
LRTI in infancy were included in the subgroup analysis and compared with controls, it turned 
out that 33% of former RSV bronchiolitis patients had doctor-diagnosed asthma, which was 
significantly more often compared to controls (17%). Significant differences were not found 
between the RSV pneumonia group and controls. In line with our results, an increased risk for 
respiratory symptoms and atopy has been found in children who presented RSV LRTI with 
wheezing in early childhood but not in those who presented crepitations in auscultation during 
infection (Elphick et al. 2007). Our classification was a little different, but altogether it seems 
that wheezing provoked by RSV is an important indicator for further asthma risk. Thus, 
underlying host factors are likely to determine, at least partly, which children are about to 
wheeze during viral infection (Elphick et al. 2007, Bonnelykke et al. 2015). It has been suggested 
that these host affect the future asthma risk more than the virus itself (Elphick et al. 2007, 
Bonnelykke et al. 2015, Thomsen et al. 2009, Kuehni et al. 2009, Beigelman & Bacharier 2013), 
and our results give undirect suppot to this hypothesis.  
 Different kinds of lung function abnormalities in later life have been found 
depending on the viral etiology of bronchiolitis. Rhinovirus bronchiolitis has been associated 
with bronchial hyperreactivity (Kotaniemi-Syrjanen et al. 2008), whereas irreversible 
obstruction (Sigurs et al. 2010, Sigurs et al. 2005) or more restrictive pattern (Hyvarinen et al. 
2007) has been demonstrated after RSV bronchiolitis. In the present study, FEV1% and 
FEV1/FVC% were reduced before and after RSV LRTI compared to controls without differences 
in bronchial reversibility after bronchodilatation. Whether these differences, or lung function 
impairment overall, are caused by viruses remains an unanswered question. A comparable lung 
function impairment has been described to be present before and after bronchiolitis at very 
early ages suggesting that bronchiolitis itself is not a determinant of future lung function 
(Turner et al. 2002). On the other hand, there is clear evidence that RSV itself is capable of 
causing damage to airways that leads to bronchial hyperreactivity, peribronchial and 
perivascular inflammation, and subepithelial fibrosis several months after the initial infection in 
mice (Jafri et al. 2004, You et al. 2006). Severe forms of RSV LRTI are characterized with severe 
small airway inflammation containing mixtures of inflammatory cells, fibrin, edema and mucus 
(Bem et al. 2011, Johnson et al. 2007). Allergic sensitization combined with viral infection or 
very early primary viral infection can lead to TH2-biased immune responses in the lungs. This 
is characterized by increased type-2 cytokine production, airway eosinophilia and remodelling 
(You et al. 2006, Becnel et al. 2005, Schneider et al. 2012, Hong et al. 2014, Siegle et al. 2010, 
Culley et al. 2002, Dakhama et al. 2005).  
 Taken together, the findings of the numerous birth cohorts and post-bronchiolitis 
cohorts have established that lung function impairment is present after early childhood LRTI. In 
the present study, irreversible obstruction was found in study subjects with a history of RSV 
LRTI. Animal models have demonstrated that viruses such as RSV and HRV are capable of 
altering pulmonary function and exacerbating pulmonary immunopathology, especially in the 
presence of other contributing factors like allergic sensitization or a very young age at the time 
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of the primary infection. However, at least part of the lung function deficits, which are also seen 
in post-bronchiolitis studies, seem to reflect premorbid changes in the airways,. 
 
6.4.2 Risk factors for asthma and lung function impairment 
Overall, many assumed early childhood risk factors for development of subsequent asthma had 
lost their significance in adulthood in the present study. This finding is in line with the recent 
follow-up of the Swedish post-bronchiolitis cohort that identified only parental asthma and 
female gender as risk factors for adulthood asthma, while other assumed risk factors had lost 
their significance (Goksor et al. 2015). This may be explained by the fact that patients with 
infant bronchiolitis have faced numerous disease modifying factors during the subsequent 30-
year follow-up. 
 As asthma risk factors were evaluated in the present study in relation to 
subsequent asthma in adulthood, early or current clinical atopy did not play a role as risk 
factors. Clinical atopy, defined as combined positive SPT and allergic symptoms, was common 
and found in 46-49% of study subjects, with no differences between groups. 
 Atopy is one of the most important risk factors for persistence of 
wheezing and development of asthma in childhood (Martinez et al. 1995, Kusel et al. 2007, 
Kusel et al. 2012, Jackson et al. 2012). Early atopic dermatitis or other kind of manifestation of 
atopic diseases have been included in every asthma predictive algorithms, as presented 
previously in this thesis (Piippo-Savolainen & Korppi 2008, Castro-Rodriguez et al. 2000, 
Kurukulaaratchy et al. 2003, Hafkamp-de Groen et al. 2013). Sensitization for Alternaria alternata 
at the age of 6 years (Stern et al. 2008) and atopy before the age of 2 years (Piippo-Savolainen et 
al. 2006) have been associated with increased asthma risk up to the the age period of 18-22 
years. However, our results are in line with the studies that suggest that this association turns 
insignificant in early adulthood by the age period of 25-29 years (Goksor et al. 2015, 
Ruotsalainen et al. 2010a). This may be the result of several other confounding and disease 
modifying factors as well as the rise in respiratory atopic diseases during later childhood and 
early adulthood, which affect the subsequent asthma risk after early wheezing. 
Allergy and atopy in wheezing children are strongly associated with persistent 
wheezing symtoms in adulthood as well as an increased likelihood of asthma relapse in young 
to middle adulthood (Guerra et al. 2004). Allergic asthma, which usually commences in 
childhood, has been recognized as a distinct asthma phenotype (Global Initiative for Asthma 
2014, Mathur & Viswanathan 2014). Current clinical atopy, however, was not a risk factor for 
asthma in the present follow-up or in the 25-28 year follow-up of the Swedish post-bronchiolitis 
cohort (Goksor et al. 2015). The lack of asthma phenotyping and a high prevalence of atopy 
among controls may explain these results. In the present cohort, the majority of former 
bronchiolitis and pneumonia patients presented atopic sensitization. In addition, 59% of former 
bronchiolitis patients who had asthma in adulthood presented atopy in very early childhood. In 
the bronchiolitis and pneumonia groups, all bronchiolitis patients had doctor-diagnosed asthma 
and all exept one pneumonia patient had previously diagnosed asthma. It is probable that the 
majority of asthmatic patients in our cohort represent an early-onset allergic asthma phenotype. 
 Family history of asthma has been associated with increased risk for asthma after 
early wheezing in childhood (Martinez et al. 1995, Sigurs et al. 2000) and in adulthood (Stern et 
al. 2008, Goksor et al. 2006, Sigurs et al. 2010, Piippo-Savolainen et al. 2006, Goksor et al. 2015). 
However, in the present follow-up, this association could not be demonstrated. Instead, 
repeated wheezing at the age period of 1-2 years and under 2 years of age were significant risk 
factors for asthma at the age period of 28-31 years in univariate analysis. However, all children 
who had history of parental asthma had repeated wheezing under 2 years of age, and due to 
this strong interaction, repeated wheezing in early childhood was not any more a significant 
risk factor in the multivariate analyses. Even though family history of asthma was not a 
significant risk factor for asthma, it was a significant predictor for irreversible obstruction in 
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lung function tests in adulthood, which agrees with previous studies (Piippo-Savolainen et al. 
2006, Kotaniemi-Syrjanen et al. 2008). This finding suggests a significant role for heredity in 
lung function.  
In addition to parental asthma, prenatal smoke-exposure (Piippo-Savolainen et al. 
2006, Goksor et al. 2007, Hyvarinen et al. 2007) and early atopy (Hyvarinen et al. 2007) have also 
been previously associated with lung function impairment after early childhood LRTI. 
However, both parental asthma and prenatal smoke-exposure have also been identified as risk 
factors for lung function impairment in the neonatal period (Martinez et al. 1988, Tager et al. 
1993, Dezateux et al. 1999, Murray et al. 2002, Young et al. 1991, Lodrup Carlsen et al. 1997, 
Bisgaard et al. 2009). It is probable that these risk factors found in post bronchiolitis studies 
reflect the underlying changes in the airways that have been present even before the initial 
LRTI.  
 
6.4.3. Blood eosinophils in relation to adulthood outcome  
We demonstrated that study subjects with asthma in adulthood had higher eosinophil count at 
hospital admission compared to those without asthma. Low eosinophil count (<0.25 x10E9/l) 
during bronchiolitis was a significant protective factor for adulthood asthma. In addition high 
eosinophil count (>0.45 x 10E9/l) on convalescence presented as a significant risk factor for 
asthma in adulthood. These findings are consistent with previous studies regarding the 
relationship of blood eosinophils at early age and subsequent asthma. Blood eosinophilia 
during (Kotaniemi-Syrjanen et al. 2002, Midulla et al. 2014, Ehlenfield et al. 2000) or outside 
(Castro-Rodriguez et al. 2000, Piippo-Savolainen et al. 2007a) the viral infection has been 
previously recognized as a risk factor for the development of asthma. However, a decrease in 
blood eosinophils seems to be the normal response to viral infection (Ehlenfield et al. 2000, 
Rosenberg et al. 2009), and a lack of this response predicted asthma even up to the age period of 
28-31 years in the present cohort. In line with our results, low eosinophils during infection 
(Martinez et al. 1988) or persistenty (Just et al. 2008) have been protective from persistent 
wheezing. In the present study, the associations between eosinophil levels in infancy and 
asthma or lung function deficiency in adulthood were independent from early atopic status, 
which is in line with previous findings in the Tucson birth cohort (Karakoc et al. 2002).  
It has previously been demonstrated that eosinophilic inflammation of the lungs is 
a crucial factor in the development of asthma (Rosenberg et al. 2013, Zagai et al. 2004). 
However, lung eosinophilia is not present in all asthma phenotypes (Wenzel 2012). Persistent 
eosinophilic inflammation in the lungs can lead to airway remodeling, characterized by 
increased reticular basement membrane thickness and smooth muscle hypertrophy 
(Woolnough & Wardlaw 2015). These changes eventually lead to persistent airflow limitation in 
adults with asthma (ten Brinke 2008, Guerra et al. 2008). In the present study, we demonstrated 
that blood eosinophilia during bronchiolitis is associated with irreversible airway obstruction in 
adulthood. This association could reflect eosinophil derived remodelling in the lungs of our 
study subjects. However, the peripheral blood eosinophil count is a balance between eosinophil 
production and the rate of entry of eosinophils into the lungs, so the association between blood 
and lung eosinophilia is not straightforward (Woolnough & Wardlaw 2015).  
 It has also been demonstrated that eosinophilic inflammation of the lungs is not 
present at an early age in children with wheezing in infancy (Malmstrom et al. 2013). More 
specifically, in a Finnish study, eosinophilic inflammation was not found in the bronchial 
biopsies or bronchoalveolar lavage (BAL) samples of infants with wheezing before the age of 2 
years (Saglani et al. 2005). However, in a recent study, a positive association between the 
amount of CD8+ lymphocytes and neutrophils in BAL samples and the thickness of reticular 
basement membrane in the endobronchial biopsy was found. This suggests that cells other than 
eosinophils may induce conditions required for airway remodeling in young children 
(Malmstrom et al. 2014). 
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It can be concluded that the association between early age blood eosinophilia and subsequent 
asthma is well established, and eosinopenic reaction during viral wheezing illness seems to 
protect against asthma development. In addition, blood eosinophilia during wheezing in 
childhood seems to be a risk factor for irreversible airway obstruction in adulthood. However, 
the pathologic processes that determine the development of lung function and the inception of 
asthma after early childhood wheezing are largely unknown. 
 
6.4.4 Early lung function, LRTIs and later respiratory morbidity 
It has been proposed that the development of COPD is not only due to accelerated age-related 
decline, but also due to a failure to achieve the expected peak lung function during early 
adulthood because of previous adverse exposures to childhood respiratory infections (Stocks et 
al. 2013). This proposition can be extended further and concluded that the development of lung 
function and later respiratory morbidity is a complex process in which prenatal factors (e.g., low 
birth weight (Canoy et al. 2007, Kotecha et al. 2013), familial asthma (Martinez et al. 1988, 
Young et al. 1991), or maternal smoking during pregnancy (Martinez et al. 1988, Tager et al. 
1993, Landau 2008, Lodrup Carlsen et al. 1997, Bisgaard et al. 2009, Murray et al. 1992)) 
predispose patients to low lung function in neonatal period. Early lung function impairment 
alone, or probably together with aberrant immune responses, further predisposes patients to 
respiratory infections in early childhood. These alone, together or in interaction with passive or 
active smoking or atopic heredity, may cause further damage and remodeling of the lungs 
which may lead to impaired lung function and respiratory morbidity in later life (Figure 8). 
 
 
 
                   
Impaired immunology and early atopy:
-Impaired antiviral response
- underlying allergic inflammation
Recurrent viral
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Atopy
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Asthma in adulthood
Impaired lung function at birth
Prenatal factors:
-Prenatal smoke exposure
- Preterm birth
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Passive or
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Airway damage and remodelling
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Figure 8. Risk factors affecting the adverse adulthood outcome of early childhood respiratory 
infections. In the favorable situation, a “healthy”, not predisposed child gets a viral LRTI in early 
childhood, and the symptoms resolve after the acute phase. However, in other circumstances, low 
infantile lung function and impaired immunology predispose the subject to LRTIs in infancy. During 
the rapid lung development at early age LRTIs alone, together or in interaction with factors like 
passive and/or active smoking or atopic inflammation, cause airway remodeling and predispose to 
lung function impairment and to the development of asthma and/or COPD in adulthood.1IUGR, 
Intrauterine growth retardation 
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6.5 HEALTH-RELATED QUALITY OF LIFE AFTER LRTI IN EARLY CHILDHOOD 
6.5.1 Impaired HRQoL after early childhood LRTI 
Studies about HRQoL after early bronchiolitis or pneumonia are scarce. The longest follow-up 
so far has been 3 years with RSV bronchiolitis patients (Bont et al. 2004). These children 
presented impaired quality of life after RSV bronchiolitis (Bont et al. 2004). In addition, 
pneumonia has been described to affect HRQoL in the short term in children (Shoham et al. 
2005). 
 Our own questionnaire was not sensitive enough to find differences in respiratory 
symptoms between the groups, such as repeated wheezing, chronic night cough, or prolonged 
cough. However, symptom scores in the SGRQ were significantly higher in former bronchiolitis 
and pneumonia patients compared to controls; this suggests an increased prevalence of 
respiratory symptoms after early childhood LRTI. Also, in the bronchiolitis group, the activity 
scores, which describe activities limited by respiratory symptoms and impact scores that 
describe social and psychological burden of respiratory symptoms, were increased compared to 
controls. Both bronchiolitis and pneumonia patients had higher total scores in SGRQ, reflecting 
impaired HRQoL in adulthood after early childhood LRTI.  
 SGRQ scores have been demonstrated to correlate with lung function and have 
been validated in several studies (Jones et al. 1991, Jones et al. 1992, Bae et al. 2011). In previous 
trials, the difference of 4 or more points in the SGRQ total score has been considered clinically 
significant (Jones et al. 1991, Jones 2005).  The scores of the former bronchiolitis patients were 
3.9 points higher compared to controls. Pneumonia patients had 3.4 points higher total scores 
compared to controls. This means that the SGRQ findings of the present study at 28-31 years of 
age after bronchiolitis or pneumonia in infancy are probably clinically significant, especially in 
term of bronchiolitis patients. This finding is strengthened by the fact that decreased HRQoL 
found after early childhood bronchiolitis or pneumonia in the present study is in line with the 
previously described findings of impaired airway function in this thesis. 
 In previous studies, SGRQ scores have been higher in smokers than in non-smokers 
(Ferrer et al. 2002, Spencer et al. 2001). However, when the results of the SGRQ data were 
categorized and adjusted with smoking, our results did not change. These analyses suggest an 
independently significant role of early childhood LRTI on HRQoL in adulthood. In addition, the 
further analysis that included only study subjects with RSV LRTI in early childhood revealed 
that RSV LRTI is also an independent risk factor for impaired HRQoL in adulthood. 
6.6 MAIN STRENGTHS AND SHORTCOMINGS OF THE STUDY 
6.6.1 Strengths of the study 
The main strength of the present study is the long follow-up time from early childhood until 
adulthood. In fact, this 30-year follow-up is thus far the longest ongoing prospective post-
bronchiolitis study. Kuopio University Hospital serves as the only hospital offering inpatient 
care for children in the area. So, even though the cohort was higly selected, including only 
hospitalized bronchiolitis and pneumonia patients, it is a representative sample of severe forms 
of LRTI.  
 Early childhood data was collected carefully and prospectively during repeated 
early childhood visits. At the time of the hospitalization, viral and bacterial samples were 
included in the study protocol, and methods were advanced at the beginning of the follow-up 
thirty years ago, including viral antigen assays from NPA´s and antibody assays from paired 
serum samples (Korppi et al. 1986, Korppi et al. 1991). Blood eosinophils were measured twice: 
at the time of the hospitalization and outside the infection. This enabled the analysis on the 
relationship between blood eosinophils and later asthma or lung function.  
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Later childhood and early adulthood data has been collected in well-conducted questionnaire 
studies and clinical follow-up visits (Piippo-Savolainen et al. 2004, Korppi et al. 1993, Kuikka et 
al. 1994, Korppi et al. 1994, Hyvarinen et al. 2005, Ruotsalainen et al. 2010a). The clinical follow-
ups have included spirometry and prick tests from the 10-year follow-up onwards (Piippo-
Savolainen et al. 2004, Korppi et al. 1994).  
 The clinical study at the age period of 28-31 years included a structured 
questionnaire, the widely used and validated SGRQ, home PEF monitoring, prick tests, FENO  
measurement, and spirometry. Spirometry was performed according to the international 
standards (Miller et al. 2005) before and after bronchodilatation by a trained respiratory nurse 
of the research group. The same spirometer was used in all measurements, making the 
evaluation of lung function parameters reliable. The 30-year follow-up was appropriately 
controlled, since age- and sex-matched population controls who were born in the same area 
were examined by an identical way as cases. 
  
6.6.2 Shortcomings of the study 
The main shortcoming of the study was undoubtedly the small number of subjects, especially in 
the groups of former bronchiolitis and pneumonia patients. We were able to contact 48/83 (58%) 
of the former bronchiolitis patients and 22/44 (50%) of the former pneumonia patients. The 
attendance rate was acceptable for a thirty-year follow-up, but the numbers are small, since the 
original study groups were also rather small. There is a risk for type 2 error, especially in 
subgroup analyses, which were therefore made with caution. 
 The number of clinically examined controls was sufficient; however, the 28% 
participation rate in the control group was rather low. This can be seen as a selection of controls, 
since the asthma prevalence in the controls was 10-15%, which is higher than the asthma 
prevalence in non-selected Finnish young adults  (Huurre et al. 2004)). Thus, the results may be 
biased to the direction of under-estimation, rather than over-estimation, of the differences 
between the bronchiolitis or pneumonia cases and the controls. Because the population-based 
controls were not recruited at the beginning of the study, it was not possible to compare early 
risk factors between bronchiolitis or pneumonia groups and controls or present longitudinal 
analysis of lung function parameters between the study groups. 
 Finnish reference values for lung function (Viljanen et al. 1982), which were used in 
the previous adulthood follow-up of the study (Piippo-Savolainen et al. 2004) are old, but new 
reference values for the Finnish population were not available at the time of the study. As 
irreversible obstruction was used as a categorized variable, we decided to also use recently 
published, multi-ethnic, age-, sex- and height-adjusted GLI 2012 limits for the abnormal 
FEV1/FVC –ratio (Quanjer et al. 2012). The use of two reference values may cause some 
confusion when evaluating the results. However, despite the reference values used, the results 
in regard the prevalence of irrebersible airway obstruction remained unchanged. 
 The definition of the RSV LRTI group was based on positive RSV antigen or 
antibody testing (Korppi et al. 1986). In addition, we included those children who were 
hospitalized during RSV epidemics for bronchiolitis or pneumonia, but had negative viral 
testing. We assumed that most of these children were RSV positive because the methods for 
viral testing were not as sensitive as the polymerase chain reaction test currently available 
(Popow-Kraupp & Aberle 2011). However, this definition of the RSV group is more inaccurate 
than if it was based solely on viral testing. 
A surprising finding was that both former bronchiolitis and pneumonia patients 
smoked regularly more often than controls. Former bronchiolitis patients had also smoked 
significantly more pack-years compared to controls, which means heavier and more long-
lasting smoking. In year 2010, the daily smoking rate in the Finnish population-based survey 
was 19% among young adults (Helakorpi et al. 2011), so the 12% smoking rate in population 
controls was slightly less. Smoking is the most important risk factor for the development of 
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chronic airway obstruction, characteristic for COPD, and the harmful effects of smoking on 
respiratory symptoms and lung function abnormalities have been widely documented (Global 
Initiative for Asthma 2014, Landau 2008, Mullane et al. 2013). A harmful interaction between 
the RSV LRTI in childhood and smoking in later life relation to adulthood asthma has also been 
demonstrated (Voraphani et al. 2014). There were some concerns that differences found 
between groups in smoking rates might affect our results, as it regards asthma prevalence and 
lung function. However, it has been documented that in smokers a greater than age-related 
decline in lung function will occur from the fourth decade of life onwards (Landau 2008). All 
our main outcomes were adjusted with current daily smoking and smoked pack years. These 
adjustments did not change our main results, and as the statistics were carefully performed, one 
can say that the differences found between study groups are independent of smoking. 
 
6.6.3 Summary 
In conclusion, carefully and prospectively collected data of the present study from early 
childhood up to adulthood provides unique information about the long-term outcome of 
hospitalized early childhood bronchiolitis and pneumonia in a clinical setting. Especially 
negative results have to be interpreted with caution due to the small number of study subjects. 
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7 Conclusions 
In the present study we evaluated the adulthood respiratory outcome in terms of asthma 
prevalence, lung function, and HRQoL in study subjects who had been hospitalized for 
bronchiolitis or pneumonia at less than 2 years of age. We investigated the effect of RSV 
etiology of initial LRTI on these outcomes. In addition, we indentified potential risk or 
protective factors affecting these outcomes in adulthood. 
 Asthma prevalence of 31-35% after bronchiolititis in early childhood was 
significantly increased compared to 11-15% asthma prevalence in the control group. Asthma 
prevalence was not increased after pneumonia in early childhood compared to controls. 
Asthma prevalence remained stable between the 20- and 30-year follow-ups of the present 
cohort.  
Lung function was impaired after early childhood bronchiolitis and pneumonia 
compared to population controls with no history of early childhood LRTI. FVC%, FEV1%, and 
FEV1/FVC-ratio% were all reduced in former bronchiolitis patients, and FEV1% was reduced in 
pneumonia patients before and after bronchodilatation. These findings demonstrate irreversible 
airway obstruction in adulthood after early childhood bronchiolitis. In pneumonia patients, 
these findings were not so obvious, but they were of similar type.  
 HRQoL as measured by SGRQ is impaired in adulthood after early childhood 
bronchiolitis and pneumonia. Pneumonia patients had higher symptom scores compared to 
controls, whereas bronchiolitis patients had higher symptom activity and impact scores 
compared to controls. 
 Asthma prevalence after RSV LRTI was increased only if wheezing was present 
during the initial LRTI in early childhood. It seems that wheezing provoked by RSV is an 
important indicator for further asthma risk rather than RSV infection itself. Irreversible airway 
obstruction and impaired HRQoL are present in adulthood after early childhood RSV LRTI. 
 Most assumed early life asthma risk factors were non-significant at the age period 
of 28-31 years, so these risk factors seem to lose their importance with increasing age. Even 
though family history of asthma was not a significant risk factor for asthma, it was a significant 
predictor for lung function impairment in adulthood. 
 Study subjects with asthma in adulthood had a higher blood eosinophil count in 
admission to hospital for bronchiolitis compared to those who did not develop asthma. In 
addition, low blood eosinophil count during bronchiolitis protected from adulthood asthma 
and high blood eosinophil count during bronchiolitis was associated with irreversible airway 
obstruction. These findings highlight the importance of eosinophil-mediated inflammation in 
the development of asthma and lung function impairment in children with the history of early 
childhood bronchiolitis. 
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childhood have been associated with 
respiratory morbidity in adulthood, 
but the prospective research 
evidence in this area is limited. This 
longitudinal 30-year follow-up study 
investigated the adulthood outcome 
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patients who were hospitalized 
at less than 2 years of age. The 
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